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ABSTRACT 
Circulating blood lipids are well-established risk factors for cardiovascular diseases. 
Levels of high-density lipoprotein, low-density lipoprotein, total cholesterol, and 
triglycerides are affected by environmental and genetic factors. As the genetic factors 
explain around half of the population lipid variation based on twin studies, knowledge 
of the genetic determinants is crucial in prevention and early treatment of harmful 
lipid levels. 
In this thesis, genetic markers associated with lipid levels were screened using 
genome-wide marker datasets to better understand the biological and heritable 
mechanisms behind lipid levels. To identify different types of associated loci, 
genome-wide single nucleotide polymorphism (SNP) data from multiple European 
cohorts was combined. In addition, this thesis presents the effect of using Finnish 
imputation panel as reference on the quality of genotype imputation, which enables 
the usage of denser SNP marker sets in association analysis.  
In total, 95 genetic loci with genome-wide significant association (P-value < 5×10-8, 
accounting for one million independent tests) on lipid levels were identified. In one of 
these loci, the SNP genotype modified the association between total cholesterol and 
waist-to-hip ratio. Common genetic markers found in the first publication together 
with the previously associated loci in publications of other research groups explained 
up to 4.8% of the lipid level variation. When combining all the genetic information 
available from different sources at the end of this thesis project, up to 16.6% of the 
trait variation could be explained, which corresponds to 33% of the trait heritability. 
In the work described in this thesis almost a hundred genetic loci associated to 
circulating blood lipids were successfully identified using large-scale genome-wide 
approaches. This thesis demonstrates new biology behind lipid levels, in addition to 
how large scale studies with dense SNP panels enabled by genotype imputation, can 
be a key in revealing biological determinants behind complex diseases and traits.  
Keywords: Circulating blood lipids, genome-wide association, gene-environment 
interaction, genotype data imputation 
 
TIIVISTELMÄ 
Verestä mitattavat lipidiarvot ovat hyvin tunnettuja riskitekijöitä sydän- ja 
verisuonitaudeille. Veren ”hyvä” kolesteroli, (high-density lipoprotein cholesterol), 
huono kolesteroli (low-density lipoprotein cholesterol), kokonaiskolesteroli sekä 
triglyseridit, ovat monitekijäisiä muuttujia, joihin vaikuttavat sekä ympäristö että 
perinnölliset tekijät. Koska perinnölliset tekijät selittävät noin puolet 
kolesterolitasojen normaalivaihtelusta, on hyvin olennaista ymmärtää 
kolesterolitasojen geneettinen tausta, jotta henkilöt joilla on korkeampi riski sairastua 
erilaisiin rasva-aineenvaihdunnan häiriöihin voitaisiin aikaisemmin tunnistaa ja siten 
epäsuotuisia kolesterolitasoja ehkäistä ja hoitaa. 
Jotta veren lipiditasojen taustalla olevia perinnöllisiä mekanismeja voitaisiin 
paremmin ymmärtää, tässä väitöstyössä on kartoitettu koko perimänlaajuisesti yleisiä, 
ympäristön kanssa vuorovaikuttavia sekä harvinaisia yhden emäksen variaatioita, 
joilla on yhteys mitattuihin lipidiarvoihin. Lisäksi on tutkittu populaatiokohtaisen 
referenssin käytön vaikutusta markkeritiedon tilastollisessa täydentämisessä, 
imputaatiossa, joka mahdollistaa tarkemman geenimarkkeriaineiston käyttämisen 
kartoitustutkimuksissa.  
Kaiken kaikkiaan onnistuimme löytämään 95 perimän kohtaa, joilla on tilastollisesti 
merkitsevä yhteys veren lipidiarvoihin ja yhdessä näistä kohdista löydetyn geneettisen 
markkerin eri muodot säätelivät vyötärö-lantio-suhteen ja kokonaiskolesterolin välistä 
yhteyttä. Ensimmäisessä osatyössä kartoitetut yleiset geneettiset markkerit selittivät 
4.8% lipidien kokonaisvariaatiosta, mutta väitöstutkimuksen lopussa yhteen kerätyt 
geneettiset variaatiot selittivät jopa 16.6% kokonaisvariaatiosta, joka vastaa noin 
33%:a kyseisen lipidin estimoidusta periytyvyydestä. 
Väitöstutkimuksessa saatujen tulosten avulla olemme oppineet paljon uutta veren 
rasva-aineenvaihdunnan biologiasta sekä näyttäneet, että suuret ja tiheämarkkeriset 
geneettiset aineistot voivat olla avain myös muiden monitekijäisten tautien 
periytyvyyden selvittämiseen. 
Avainsanat: Veren lipidimittaukset, perimänlaajuinen assosiaatioanalyysi, geeni-
ympäristö-interaktio, geenimarkkeriaineiston imputaatio  
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1000G    1000 Genomes project 
ABCA1   ATP-binding cassette transporter A1  
APOA1   apolipoprotein A-I  
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HM2    HapMap project phase 2  
HM3    HapMap project phase 3  
HMM    Hidden Markov Model 
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IBD    identity by decent 
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IBS    identity by state 
IDL    intermediate-density lipoproteins 
IMT    Intima media thickness 
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LDLR    LDL receptor 
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MDS     multidimensional scaling 
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NMR    nuclear magnetic resonance 
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pre-mRNA   precursor messenger RNA 
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RNA    ribonucleic acid 
siRNA    small interfering RNA 
SNP    single nucleotide polymorphism 
TC    total cholesterol  
TG    triglycerides 
VLDL    very low-density lipoprotein 
WHR    waist-to-hip ratio 
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1 INTRODUCTION 
Cardiovascular diseases, the leading cause of death worldwide, have been under great 
interest for epidemiological studies. In 1961, the first epidemiological publication by 
Framingham study was published, showing risk characteristics for multiple factors 
affecting cardiovascular diseases (Kannel et al. 1961), but still over 50 years later the 
preventative actions for these diseases are limited and are mainly concentrated on 
lifestyle changes. In clinical practice, the most often used biomarkers for 
cardiovascular diseases are the circulating blood lipid levels. 
Circulating blood lipid levels are complex traits affected by multiple environmental 
factors like diet, body composition, smoking, and alcohol usage. The risk for 
unfavorable lipid levels caused by these factors can be lowered by individual’s 
behavioral changes (Webb et al. 2013). However, only a bit less than a half of the 
variability in lipid levels is attributable to these environmental factors (van Dongen et 
al. 2013) and the remaining proportion is because of the genetic effects. Therefore it 
is crucial to understand the genetic mechanisms behind the lipid levels in order to 
better understand the biological pathways behind cardiovascular diseases. 
Since the early 1970s (Kuivenhoven and Hegele 2014), genetic studies of blood lipids 
have found multiple genetic markers associated with blood lipid levels by comparing 
the genome sequence of individuals with severe dyslipidemia. These markers have 
often been found close to or in genes coding for well-known enzymes or lipoprotein 
sub-particles. Though these genetic markers explain the deranged cholesterol values 
in the dyslipidemic patient or family, their contribution to general population lipid 
level variation has not been thoroughly examined. 
To better understand the overall population variation of lipid levels and other complex 
traits, genome-wide association analyses in unrelated healthy individuals have been 
initiated. These genome-wide analyses have been enabled by the revelation of the 
human genome sequence in 2001 by two independent projects (Lander et al. 2001, 
Venter et al. 2001). The initial genome-wide association studies were performed using 
single population cohorts with a few thousand individuals; and it quite soon became 
clear that the genetic effects of genetic factors affecting complex diseases were too 
small in the general population to be found using datasets of that size. 
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In this thesis project, multiple genome-wide datasets of European origin, comprising 
of a maximum of 62,000 samples, were used to further reveal the genetic background 
and to further understand the biology behind the general population lipid level 
variation.    
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2 REVIEW OF LITERATURE 
2.1 Human genome 
2.1.1 Genome structure 
The human genome can be found in almost every cell in the body inside the nucleus 
as 23 chromosome pairs (total 46 chromosomes). Each chromosome is a double 
stranded histone packed deoxyribonucleic acid (DNA) string built with smaller 
particles; nucleotides. There are four different types of nucleotides in DNA, defined 
by the base that is attached to the sugar phosphatase backbone. The four possible 
bases are adenine (A), guanine (G), cytosine (C), and thymine (T). The double 
stranding of the chromosomal DNA is achieved by complementary base pairing, 
adenine always binds with thymine and cytosine with guanine. This structure ensures 
that both strands have the same information, which can be useful if an error in DNA 
sequence occurs during cell division. The whole human genome consists of 
approximately 3 billion base pairs of which only 1.5% is covered by exons (Lander et 
al. 2001), regions that are transcribed to mature ribonucleic acid (RNA). The 
remainder of the DNA is untranslated, intronic, and intergenic DNA, all known to 
greatly affect how and when a particular gene is functioning in the cell (ENCODE 
Project Consortium et al. 2012). 
2.1.2 Genome function 
A gene is a chunk of DNA that has promoter, exons, and introns. Exons are the parts 
of the gene that define the amino acid structure in the resulting protein. The exonic 
DNA has triplets of nucleotides, called codons, each of which has a corresponding 
amino acid. In gene transcription, an enzyme, RNA polymerase together with 
transcription factors bind to the core promoter and form a transcription initiation 
complex which splits the double strand of the DNA and starts the transcription 
(Figure 1). In case of a protein coding gene, RNA polymerase starts to move along the 
template strand (non-coding strand) of the DNA and copies it into precursor 
messenger RNA (pre-mRNA) starting from a start codon and ending at a stop codon. 
The structure of the resulting single stranded pre-mRNA is similar to that in the 
coding DNA strand, except that base thymine is replaced with uracil (U). 
Review of literature 
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Figure 1. From DNA to protein. Demonstrative figure of transcription and translation of a 
protein coding gene. 
Once the pre-mRNA is ready, the introns are spliced out from the sequence and the 
mRNA moves outside of the cell nucleus to the cell cytoplasm where it binds to the 
ribosome. The ribosome starts to translate the genetic code in the mRNA into amino 
acid code. Each of the codons, except for stop codons, has one pairing amino acid. In 
contrary, one amino acid can have multiple corresponding codons allowing a 
mutation to occur in the genome without changing the protein structure. 
2.1.3 Genetic variation 
Mutation is a change in DNA sequence occurring during meiosis or because of 
radiation or mutagens, and which has escaped the DNA repair system. When non-
fatal mutation occurs, it can be passed on to the next generation and when the 
frequency of the mutated allele in the population rises up to 1%, the mutation is called 
a polymorphism. In this thesis, mutations with lower population frequency are also 
referred to as polymorphisms to simplify the concepts. 
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2.1.3.1 Mutation types 
One way to classify mutations is based on their effect on the DNA structure. Using 
this classification, there are five main types of mutations: point mutation, insertion, 
deletion, translocation, and inversion.  
The most common of these is the point mutation, where one nucleotide changes to 
another. If point mutations occur in an exonic region they can be one of three 
subtypes: missense mutation (changes amino acid sequence), nonsense mutation 
(changes amino acid codon to stop codon) or silent mutation (does not affect the 
amino acid chain). Missense and nonsense mutations can be further classified to loss-
of-function, gain-of-function or neutral mutations based on the changes in protein 
function. 
Insertion is a mutation where a fragment of DNA is added to the genome and deletion 
is a mutation where a fragment of DNA is lost. Both insertions and deletions usually 
occur during DNA replication in cell division. These two mutations can vary highly 
by the size of the DNA fragment being from 2 bases to even 100k bases. If the length 
of the DNA fragment deleted or inserted to the genome is not divisable by three and is 
positioned within the gene, the mutation can be a frame-shift mutation. Frame-shift 
mutations change the protein structure drastically as every amino acid from the 
beginning of the mutation is likely to be changed to another. In addition, large 
deletions and insertions can double or remove whole genes, and in these cases the 
effect on individual’s phenotype can be more severe than in the case of shorter 
structural mutations. 
In translocations, two chromosomes change part of the DNA with each other. 
Translocations can be balanced, where an equal amount of DNA is changed, or un-
balanced, where part of the DNA gets lost in the exchange. In inversions, part of the 
DNA is shifted around at its place. Translocations are usually large-scale mutations 
and can lead to very severe phenotypes like cancer (Bunting and Nussenzweig 2013).  
Translocations can appear during meiotic cell division where they can lead to fertility 
problems (Madan 2012). 
2.1.3.2 Measuring genetic variation 
Most of the large chromosomal changes, like translocations, inversions, and large 
deletions and insertions, can be detected with karyotype staining. In karyotype 
Review of literature 
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staining, the chromosomes are stained using a suitable dye showing clear bands in the 
chromosomes. Comparing the stained karyotype of a patient to a normal karyotype, 
possible differences in band patterns, length or the amount of chromosomes can be 
detected.  
Smaller mutations are harder to detect and require more advanced methods. Before 
the breakthrough in 2001, when the human genome was fully sequenced for the first 
time (Lander et al. 2001, Venter et al. 2001), most studies were concentrating on 
specific candidate genes and only genes of interest were sequenced. The whole 
genome sequence and mapping of the recombination rate across different genomic 
sites (International HapMap Consortium 2005) made it possible to design genotyping 
chips, by which multiple single nucleotide polymorphisms (SNPs) and copy number 
polymorphisms (CNPs, small insertions, and deletions) covering most of the genome 
variation could be measured with reasonable costs. In the early stages of chip 
genotyping, approximately 300,000 common polymorphisms were measured with one 
chip but nowadays the number is over a million polymorphisms. 
2.2 Population genetics 
Population genetics, first introduced by R.A Fisher, and Mendelian inheritance, 
introduced by G. Mendel, describe how genetic material is transmitted through 
generations. Population is defined by a group of individuals of the same species that 
can breed with each other. This means that in addition to species, physical distance 
can separate populations from each other. For example, a beehive can be considered 
to have one population of bees.  
2.2.1 Meiosis and recombination 
In meiosis, a diploid cell with two copies of each chromosome, one from mother and 
one from father, divides twice producing four haploid gametes each carrying only one 
of each chromosome (total 23). Recombination in meiosis causes all people to be 
unique by mixing the genetic material between two copies of a chromosome and thus 
creating a unique combination of genetic material. Only monozygotic (identical) 
twins share the exact DNA sequence as they have evolved from the same pair of 
haploid gametes. 
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In the first cell division, the diploid cell divides into two haploid daughter cells with 
double the number of chromatids, which are kept tightly together until the second cell 
division where the chromatids are separated. The first division starts with DNA 
replication, where each of the chromosomes (N = 46) is copied into two sister 
chromatids, which are attached to each other by a centromere (Figure 2). Then the 
two chromosomes of a pair get to close proximity and prepare for cell division. At 
this point, recombination of the genetic material happens. While the chromosomes are 
close to each other, they can cross over at points called chiasmata and when the two 
chromosomes are drawn away from each other, parts of the chromosomes get mixed. 
After this point there are two cells with 23 chromosomes and 46 chromatids with 
unique recombination of the genetic material.  
 
Figure 2. Meiosis and recombination. 
In the second cell division, sister chromatids are separated from each other into 2×2 
haploid gametes, each with 23 chromosomes and 23 chromatids. As each of the 
chromatids in the first cell division crossover independently, these four gametes are 
all unique. In fertilization, two gametes, one from mother and one from father, are 
combined resulting in a diploid cell with 46 chromosomes and 46 chromatids. 
Review of literature 
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2.2.2 Mendelian inheritance 
Gregor Mendel, an Austrian monk, defined the laws of inheritance by crossing garden 
peas between 1856 and 1863. Though the results were published already in 1866, the 
research community did not acknowledge the laws of inheritance until 1900 when 
three European scientists re-discovered the results found by Mendel based on similar 
crossing and breeding studies, and W.H. Bateson defined word “genetics” (from Latin 
“gen” = “race of a kind”) and “allele” (from Latin “alius” = “other”). 
The Law of Segregation, also known as the first law of Mendelian inheritance, stated 
that every diploid individual has two alleles for particular trait, inherited from parents, 
one from mother and other from father. A pair of alleles is called genotype, whereas 
the individuals’ appearance is called phenotype. Individuals carrying two copies of 
the same allele are called homozygous and individuals with two different alleles are 
called heterozygous. In dominance model, one of the alleles is dominant (A) over the 
recessive allele (a), meaning that the phenotype of heterozygous individual is solely 
defined by the one dominant allele and the recessive phenotype is only seen in 
individuals with two recessive alleles. In co-dominant model, where each allele has an 
equally strong effect on the phenotype, the appearance of a heterozygous individual is 
in between the two homozygous phenotypes. 
The Law of Independent Assortment, also known as the second law of Mendelian 
inheritance, stated that different traits are inherited independently. Using dihybrid 
crossing, Mendel noticed that in case of two dominant phenotypes, the offspring 
phenotype ratio was 9:3:3:1, and ratios of the two distinct phenotypes were both 3:1, 
and concluded that alleles of these two traits are independently passed from 
generation to generation. As was later demonstrated by T. H. Morgan, this law applies 
only to alleles that are not linked in the genome. 
2.2.3 Genetic linkage and linkage disequilibrium 
When two loci are positioned close to each other in the genome, they are more likely 
to be inherited together than loci with long physical distance, as the probability for 
chiasma increases with distance. Alleles that are not independently inherited are said 
to be linked with each other.  
Bateson first observed the linkage of two alleles, but Morgan was the first one to 
notice that the probability of two alleles to be inherited together varies, and concluded 
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that the probability for recombination could represent distance of the loci in the 
genome. This distance, known as genetic distance, is measured with cM 
(centimorgan) units, which represent the expected number of recombinants in 100 
gametes.  
Whereas genetic linkage represents the association between two genomic loci in the 
same chromosome and within pedigree by the probability of recombination, linkage 
disequilibrium (LD) measures the probability of two alleles to be seen together in the 
same haplotype in a population. Haplotype is a chunk of DNA that originates from a 
common ancestor. LD is affected by genetic linkage, but also by natural selection, 
mutation rate, genetic drift and other population genetics phenomena. LD is usually 
measured with D’ or r. 
Let us think of two genomic loci, A and B, which both are biallelic with possible 
alleles 1 and 2. The possible four haplotypes are in this case !!!!, !!!!, !!!!, and !!!!. Let us denote the frequencies of these haplotypes in the population by !!!, !!", !!", and !!!, respectively. If we further define the population frequency of allele !! as ! and of allele !!  as ! , the joint probability to detect haplotype !!!!  assuming 
independence between the two loci is !". Measure ! (Lewontin and Kojima 1960) 
denotes the difference of the joint probability from the observed frequency and thus  ! = !!! − !". 
Based on a suggestion by Lewontin (Lewontin 1964), to ensure the range of D values 
to be between 0 and 1, D is normalized using its maximum value,  
!! = !!!"# !! ,!
where  
!!"# = min !", 1− ! 1− ! ,when! < 0min 1− ! !,! 1− ! ,when! > 0!!. 
 
The other measure used to present LD, !, is defined 
! = !!"(1− !)(1− !)!!. 
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2.2.4 Allele sharing 
Allele sharing is a measure between two individuals in particular locus. Identity by 
state (IBS) tells how many alleles two individuals share and identity by decent (IBD) 
how many alleles two individuals have inherited from a common ancestor. This 
means that IBS ≥ IBD. For example in the Figure 3 below, individuals 8, 10, and 12 
have inherited allele A from a common ancestor 1 and thus share that allele IBD. 
Individual 11 has same allele in that locus but due to a mutation and thus shares the 
allele A IBS but not IBD with 8, 10, and 12. 
 
Figure 3. Family tree demonstrating allele sharing IBS and IBD. 
When considering SNP data, each individual has two alleles at a specific locus 
meaning that IBD and IBS between two individual can be 0, 1, or 2. These measures 
can also be represented using proportional measures, in which case the possible 
values are 0, 0.5, or 1. IBD sharing can be estimated with certainty only using family 
data but can be estimated in population-based samples as well (Milligan 2003). When 
using population-based samples, high relatedness between individuals is often 
checked to identify contaminated samples (high relatedness to multiple other samples) 
or relatives that the dataset is not supposed to contain. In population-based samples, 
IBS sharing based clustering or multidimensional scaling (MDS) can be used to 
identify subpopulation structures (Purcell et al. 2007).  
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2.2.5 Hardy-Weinberg equilibrium 
One of the basic assumptions in most genetic analyses is that the genotypes of a 
specific SNP variant are in Hardy-Weinberg equilibrium (HWE). When SNP is in 
HWE, the observed genotype counts are close to the expected counts derived using 
allele frequencies. Deviations in the observed genotype counts compared to the 
expected counts can be due to natural selection, non-random mating, migration or 
genetic flow. 
The HWE is commonly tested using Fisher´s exact test, which compares the number 
of observed heterozygous genotypes to the expected number. Alternatively, Pearson’s 
chi-square test for count table can be used. As in genome-wide analyses the number 
of tested SNPs for the deviation from HWE is large. The most commonly used P-
value threshold for significant deviation is 1×10!!. SNPs with P-values less than the 
threshold are usually excluded from the analyses to avoid bad quality data. 
2.2.6 Finnish population genetics 
Finns are one of the genetically most studied populations in the world, mostly because 
of the colorful population history that has created a unique population structure with 
special characteristics. Special characteristics beneficial for genetic studies are 
founder effect due to small number of founders, bottleneck effect due to wages of war 
and famine as well as sub-population isolates due to sparse inhabitation of the 
country. 
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Figure 4. Early and late settlement in Finland 
First founders came to Finland more than 4000 years ago from the east followed by a 
second wave of founders from the south approximately 2000 years ago. The first 
wave settled to the southeastern parts of the country whereas the second wave 
populated the rest of the coastal areas (Kittles et al. 1998). In the 12th century, there 
were only approximately 50,000 Finns. In the 16th century the population reached 
250,000 but was still heavily concentrated on the coastal areas, which are thus 
commonly referred to as the early settlement (Figure 4). Because of the growing 
population and high taxation by the Swedish Crown, internal migration from the 
southeastern parts to less inhabited central and western parts and finally even northern 
parts of Finland (late settlement) started around 1500s. 
Around 17th century whole country was inhabited by approximately 400,000 Finns. 
During 1696-1698 the great famine and following disease epidemics lowered the 
population to 250,000 causing a loss of population variation commonly referred to as 
bottleneck effect. From the beginning of 18th century until today the population 
growth has been fast, from 250,000 to more than 5,400,000 in 400 years. 
The founder and bottleneck effects in Finland are seen as differential allele 
frequencies and LD structure when compared to the general European population. In 
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practice, some of the genetic variants with low allele frequencies in the European 
populations may show considerably higher allele frequencies in Finland and 
consequently have higher power for association detection in genome-wide studies 
(Kristiansson et al. 2008). On the other hand, lots of genetic variation seen in Europe 
is absent in the Finnish population restricting the total genetic variation and therefore 
easing the search for causal genetic mutations. The difference in the LD structure 
between Finnish and general European populations can been seen as longer ancestral 
haplotypes (long range LD). In addition, as parts of Finland have been sparsely 
inhabited even until today, the small villages founded during the internal migration 
era in the 1500s have been isolated from each other and have thus slowly inbred and 
formed sub-population isolates. In these isolates, allele frequencies and LD structure 
compared to the whole Finnish population can be as different as those in the central 
Europe (Jakkula et al. 2008).  
Due to these unique population characteristics, the Finnish population has a great 
variety of population and sub-population specific diseases (Norio et al. 1973) where 
the causal genetic mutations have cumulated in specific parts of Finland. These 
diseases have been easier to study in inbred sub-populations with large pedigrees and 
less haplotypic variation (Peltonen et al. 2000) and to date, 36 have been successfully 
identified. 
2.3 Circulating lipoproteins 
Each of the lipoproteins is constructed by apolipoprotein(s) that bind to different 
types of insoluble lipids. Lipoproteins themselves are soluble because of the 
phospholipid core of the particle. The lipoprotein particles have hydrophilic groups of 
phospholipids, cholesterol, and apolipoproteins directed outward making them soluble 
in the salt water-based blood pool. Triglyceride and cholesterol (as cholesterol esters) 
are carried inside of the phospholipid core of the particle. Lipoproteins are named 
based on their size and density; the lower the density, the larger the particle (Lusis 
and Pajukanta 2008, Ramasamy 2013). The following chapters about lipoproteins and 
their functions only cover the main pathways of lipid metabolism. 
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Figure 5. Lipid metabolism. Simplified flowchart presenting the connections between 
different lipoproteins and how they act as energy transporters in the blood stream. Dietary 
lipids are transported in chylomicrons to tissues. Liver triglycerides (TG) are released by 
very-low density lipoprotein (VLDL) and intermediate density lipoprotein (IDL), and 
cholesterol by low-density lipoprotein (LDL) particles to peripheral tissues. High-density 
lipoprotein (HDL) particles collect excess cholesterol from cells and transport it back to liver 
where it is converted into bile salts. 
2.3.1 Chylomicrons 
Dietary triglycerides (TG) and cholesterol are transported from the intestine in 
chylomicrons (Figure 5), the largest circulating lipoprotein particles. Depending on 
the stage of the chylomicron the apolipoprotein in the particle varies. In the nascent 
chylomicron the main apolipoprotein is apolipoprotein B-48 (APOB48). In the blood 
stream, the nascent chylomicron interacts with high-density lipoprotein (HDL) from 
which it gets apolipoprotein C-II (APOC2) and apolipoprotein E (APOE) 
transforming into mature chylomicron.  
The mature chylomicron releases most of the TG to adipose and muscle cells where it 
is stored in lipid droplets (adipose tissue) or used as energy (muscle tissue) by the 
help of the lipoprotein lipase (LPL), which hydrolyzes the TG so that the cell can 
intake it. When the TG content in the lipoprotein gets low enough, the chylomicron 
returns the APOC2 to HDL, turns into chylomicron remnant, and is taken into the 
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liver due to receptor recognition of the APOE. In the liver the remnant releases the 
remaining TG and cholesterol, and is broken down. 
2.3.2 Very-low-density and low-density lipoproteins 
If the human body has too much fatty acids or carbohydrates in the blood stream, they 
are converted into TG in the liver and packed, together with the already existing liver 
TG, into very-low-density lipoprotein (VLDL) particles. The nascent VLDL particle, 
built up in liver containing apolipoprotein B100 (APOB100), apolipoprotein C1 
(APOC1) and APOE, is released into the blood stream where, similarly to the 
chylomicrons, it interacts with HDL receiving APOC2 and another copy of APOE 
donating TG in return and turns into a mature VLDL particle.  
The mature particle continues to circulate in the blood stream and releases TG with 
the help of LPL to peripheral tissue cells similarly to the chylomicrons, but also to 
HDL particles in exchange for cholesterol by the help of cholesterylester transfer 
protein (CETP). When VLDL particles have released most of their TG, they give the 
APOC2 back to HDL and turn into VLDL remnants, also called intermediate-density 
lipoproteins (IDL).  
About half of the IDL particles are recognized by the liver receptors due to the 
APOB100 and APOE and are taken into the liver for breaking down. The other half 
loses the APOE and continues to move in the blood stream. When IDL even further 
releases TG, it will finally turn into low-density lipoprotein (LDL), which has only 
APOB100. LDL particles transport cholesterol to all tissues. The cell cholesterol 
uptake is mediated by LDL receptors (LDLR), followed by binding to the APOB100 
and APOE, and takes the LDL particle into the cell. In cell lysosomes, the cholesterol 
esters of LDL are hydrolyzed to free cholesterol and used for cell metabolism. 
2.3.3 High-density lipoproteins 
The transport of cholesterol from other tissues to the liver is facilitated by high-
density lipoprotein (HDL) particles. Nascent HDL particles are created in the liver 
with the help of ATP-binding cassette transporter A1 (ABCA1) and contain 
apolipoproteins A-I and A-II (APOA1 and APOA2). The HDL particle interacts with 
chylomicrons and VLDL particles as was described earlier. Another function of the 
HDL particle is to collect excess cholesterol from cells with the aid of ABCA1 and 
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lecithin-cholesterol acyltransferase (LCAT). Once the nascent particle has collected 
enough cholesterol, the HDL particle transports the cholesterol back to the liver where 
it is converted into bile salts. This process is called reverse cholesterol transport. 
2.3.4 Lipoproteins and health 
Because of the function of HDL and LDL particles, the enzymatically measured 
HDL-cholesterol (HDL-C) and LDL-cholesterol (LDL-C) levels are often referred to 
as “good” and “bad” cholesterol, respectively. It also explains why LDL-C levels 
have positive correlation with cardiovascular events and HDL-C levels have negative 
correlations. The excess amount of LDL and insufficient HDL lipid clearance in the 
blood stream can cause arterial inflammation leading to an atherosclerotic plaque 
blocking the artery (Badimon and Vilahur 2012). This connection between circulating 
blood lipids and cardiovascular disease risk has made lipids part of the most studied 
human traits. As the different enzymatically measurable lipid traits, HDL-C, LDL-C, 
total cholesterol (TC), and triglycerides (TG), also seem to be highly heritable (van 
Dongen et al. 2013), they have been under great interest in genetic studies. 
In addition to the connection with cardiovascular diseases, disruptions in the 
lipoprotein metabolism can cause many different kinds of dyslipidemias depending on 
the particle or enzyme that is affected. Most of these lipid related syndromes are 
monogenic (caused by a mutation in a single gene) and are thus inherited based on 
Mendelian laws. There are two major groups of lipid related syndromes, 
hyperlipidemias, where the blood lipoprotein levels are elevated, and lipoprotein 
deficiency disorders, where the lipoprotein levels are lowered. 
2.3.4.1 Hyperlipidemias 
Hyperlipidemias are syndromes where lipoprotein levels are elevated in blood and are 
classified by the Fredrickson classification (Fredrickson and Lees 1965). Type I 
hyperlipidemia, known as familial hyperchylomicronemia, is characterized by 
elevated blood chylomicron levels and therefore show as elevated TG levels in 
clinical tests. The elevation is due to LPL deficiency and multiple genetic mutations 
in the LPL gene have been shown to cause this hyperlipidemia (Ameis et al. 1991, 
Beg et al. 1990, Bertolini et al. 2000, Devlin et al. 1990, Dichek et al. 1991, 
Faustinella et al. 1991, Gotoda et al. 1991a, Hata et al. 1990, Haubenwallner et al. 
1993, Henderson et al. 1996, Hoffmann et al. 2000, Ishimura-Oka et al. 1992, 
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Kobayashi et al. 1993, Ma et al. 1991, Sprecher et al. 1992, Takagi et al. 1992, 
Wilson et al. 1983). Another hyperlipidemia showing similar phenotypic features to 
LPL deficiency, and with a recessive mode of inheritance, is APOC2 deficiency, 
subtype b in type I hyperlipoproteinemias. Instead of LPL mutations, this syndrome is 
caused by mutations in the APOC2 gene (Connelly et al. 1987, Cox et al. 1978, Fojo 
et al. 1989). 
Type II hyperlipidemia is more commonly known as familial hypercholesterolemia 
where the blood LDL-C levels are increased. This syndrome is inherited as a 
dominant disease, meaning that only one copy of the causal mutation leads to elevated 
LDL-C values. The syndrome is mainly caused by mutations in LDLR (for example 
Henderson et al. 1988, Hobbs et al. 1987, Hobbs et al. 1992, Koivisto et al. 1992, 
Koivisto et al. 1995, Kotze et al. 1990, Langlois et al. 1988, Leitersdorf et al. 1989, 
Leitersdorf et al. 1990, Meiner et al. 1991, Moorjani et al. 1993), PCSK9 (Abifadel et 
al. 2003, Hunt et al. 2000), and APOB (Innerarity et al. 1987, Pullinger et al. 1995) 
genes, but mutations in the LDLRAP1 gene have also been shown to associate with it 
(Garcia et al. 2001). 
Type III hyperlipidemia (familial dysbetalipoproteinemia) shows as increased LDL-C, 
TC, and TG levels in blood in addition to low HDL-C levels. It is mainly caused by 
homozygosity of mutations in the APOE gene (Cladaras et al. 1987, Havekes et al. 
1986, Havel et al. 1983, Lohse et al. 1992, Rall et al. 1982, Wardell et al. 1987) but 
there are studies questioning the true mode of inheritance (Mann et al. 1995, Smit et 
al. 1990). Mutations in APOE lead to unsuccessful clearance of remnant chylomicron, 
IDL, and VLDL particles and thus show as elevated enzymatically measured LDL-C 
and TG values. 
Type IV hyperlipidemia, also known as familial hypertriglyceridemia, is a dominantly 
inherited syndrome showing elevated TG values and normal cholesterol values. There 
are several genes whose mutations are known to predispose to this syndrome, for 
example APOA5 (Kao et al. 2003, Pennacchio et al. 2002) and LIPI (Wen et al. 2003). 
Type V hyperlipidemia is characterized by increased chylomicron and VLDL levels 
in blood. Compared to the other hyperlipidemia types listed above, this 
hyperlipidemia is complex syndrome affected by both genetic and environmental 
factors (Ghiselli et al. 1982). 
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2.3.4.2 Lipoprotein deficiency disorders 
Lipoprotein deficiency disorders are syndromes where lipoprotein levels are lowered 
in the blood. Abetalipoproteinemia and less severe hypobetalipoproteinemia are 
lipoprotein deficiency disorders characterized by hypocholesterolemia (low 
chylomicron, VLDL, and LDL particle levels) and vitamin absorption malfunctions 
following low lipid values in blood (Zamel et al. 2008).  Multiple genetic mutations in 
MTP (Benayoun et al. 2007, Rehberg et al. 1996, Sharp et al. 1993, Shoulders et al. 
1993, Yang et al. 1999), APOB (Hegele and Miskie 2002, Welty et al. 1991, Yue et 
al. 2002) and ANGPTL3 (Musunuru et al. 2010a, Pisciotta et al. 2012) genes have 
been associated with these syndromes. 
Familial alpha-lipoprotein deficiency, commonly known as Tangier disease, is an 
autosomal recessive lipid deficiency syndrome where blood APOA1, and thus HDL 
particle levels, are lowered. Lowered HDL levels lead to accumulation of free 
cholesterol in the blood and can lead to a myocardial infarction. Though this 
syndrome is due to lowered APOA1 levels, studies of the APOA1 gene have not 
undiscovered mutations causing the disease (Law and Brewer 1985, Makrides et al. 
1988). Instead, it seems that this syndrome is caused by mutations in ABCA1 gene 
(Bodzioch et al. 1999, Brooks-Wilson et al. 1999, Guo et al. 2002, Huang et al. 2001, 
Ishii et al. 2002, Lapicka-Bodzioch et al. 2001, Remaley et al. 1999, Rust et al. 1999), 
which encodes a protein that interacts with APOA1 to clear cholesterol from 
circulating blood. 
2.3.4.3 Other lipid metabolism disorders 
In addition to hyperlipidemias and lipoprotein deficiency disorders there are couple of 
disorders that cause change in lipid metabolism but which do not fall under the 
definition of the two major groups. 
One of these disorders is sitosterolemia, autosomal recessive disorder in which the 
absorption of cholesterol and cholesterol-like molecules, like sitosterol, is 
dysfunctioning. Mutations in ABCG5 and ABCG8 genes have been associated to this 
disorder (Berge et al. 2000, Lee et al. 2001, Lu et al. 2001). Another example is 
LCAT-deficiency disorder. In this disease, the deficiency of LCAT causes 
malfunction of HDL particles in the blood stream and can be diagnosed as low HDL-
C levels. Multiple mutations in the LCAT gene have been shown to associate with this 
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disorder (Funke et al. 1993, Gotoda et al. 1991b). Lastly, hepatic lipase deficiency 
disorder is a syndrome in which the HDL-C levels in blood are highly elevated. 
Patients of this syndrome have been found to have mutations in the hepatic lipase 
coding gene, LIPC (Hegele et al. 1991a, Hegele et al. 1991b). 
2.4 Complex diseases and traits  
Most of the diseases and traits in human populations are so called complex diseases 
and traits. The word “complex” here denotes that the there are multiple factors, both 
genetic and environmental, defining how the trait or disease appears at the individual 
level. Examples of complex traits are height, weight, and blood cholesterol levels, and 
of complex diseases are type II diabetes and cardiovascular disease. 
One of the main features of a complex trait is the quantitative nature, which depends 
on the number of underlying genetic variants or environmental factors. This applies 
for the complex diseases as well, but for diagnostic purposes the severity of the 
symptoms, or cumulative effect of both genetic and environmental factors, define the 
disease state thus making the studied variable binary. As an example of a complex 
binary trait that is defined by a single quantitative measurement with a threshold is 
hypertension where blood pressure values define whether one has the disease or not.  
2.4.1 Heritability 
As complex diseases and traits are affected by both genetic and environmental factors 
it is essential to have an estimate of how big a proportion of the total variability is 
accounted for by the genetic effects to know whether it is worthwhile to even study 
the genetic component of the trait. This estimate is called heritability of the trait. 
There are two subtypes of heritability estimates: narrow sense heritability, which 
corresponds to the additive genetic effect on the trait, and broad sense heritability, 
which corresponds to the total genetic effect allowing for gene-gene interactions, as 
well as dominant and recessive SNP-effect in the estimation model (Jacquard 1983).  
Heritability can be estimated by multiple different analysis settings depending on the 
data collection at hand. The most commonly used estimation approach is to compare 
the correlation between dizygotic (non-identical) and monozygotic (identical) twins. 
In classical twin studies, the heritability can be estimated by utilizing the fact that 
identical (monozygotic) twins share their genomes whereas non-identical (dizygotic) 
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twins only share half (on average). The environmental resemblance can be assumed to 
be similar between both twin-pair types (Martin et al. 1997). 
Another approach is to use family data, either small nuclear families or sib-pairs, or 
multi-generation family data. All these methods are based on the IBD-estimation, 
which can be performed using pedigree information or by using genome-wide marker 
data (Visscher et al. 2006). Lastly, it is possible to estimate trait heritability using 
large population based samples using genome-wide marker data by estimating the 
IBD-matrix of the sample set and comparing it to the phenotypic correlations between 
individuals (Ritland 1996). 
2.5 Genome-wide association analysis 
Genome-wide association (GWA) studies were enabled by the development of 
genotyping microarrays. With these arrays, large numbers of samples, needed for 
sufficient power to detect genome-wide association patterns, could be genotyped with 
reasonable cost. In GWA analysis, the same statistical test is applied for each of the 
genomic markers. The test and model applied depends on the sample set and trait 
distribution. In the case of population-based samples, binary traits can be tested using 
logistic regression models and quantitative traits with linear regression models 
(Balding 2006). Datasets with family structure often need more computationally 
demanding methods but offer more power due to allele segregation. For family based 
datasets, the most used tests are transmission disequilibrium test and its multiple 
generalizations (Laird and Lange 2006). 
One of the biggest problems in the GWA analyses is the multiple testing dilemma. 
When analyzing hundreds of thousands or even millions of SNPs at the same time, 
one must account for the fact that the probability to detect at least one association by 
change (type I error) rises with each independent test. However, as SNPs in the data 
are not truly independent because of the LD, a simple Bonferroni correction that 
corrects for the number of tests is highly conservative. The most powerful way to take 
the multiple testing challenge into account is to use permutation procedures; simulate 
the null distribution of the test statistics in the case of no association. However, as the 
magnitude of SNPs in the GWA analyses can be in the millions, the computational 
challenges have made it nearly impossible to use permutation in the large GWA 
studies (Rice et al. 2008). Due to these problems, Bonferroni correction for one 
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million independent tests, P-value < 0.05 / 106 = 5×10-8, is commonly used as a 
significance threshold in GWA studies  (Sham and Purcell 2014). This threshold has 
proven to work well in the published studies as most of the findings have been 
successfully replicated and it has thus become a general genome-wide significance 
threshold. 
In complex disease genetics, the associations between SNP and trait are often weak 
and thus genome-wide significant associations are hard to detect with single cohorts. 
This has forced researchers across the world to join forces and establish international 
consortia where they combine data from different research centers into huge GWA 
meta-analysis projects. These consortia projects have been extremely successful in 
screening GWA for multiple complex traits (Berndt et al. 2013, Dupuis et al. 2010, 
Global Lipids Genetics Consortium et al. 2013, Teslovich et al. 2010, Wellcome Trust 
Case Control Consortium 2007). 
In lipid genetics, the overlap between the previously well-established genetic loci 
with genes causing dyslipidemias and loci showing significant associations in 
population based GWA screens is striking (Figure 6). Out of the 20 loci for genes 
causing severe changes in lipid metabolism, 16 have also shown association in GWA 
studies. In addition, 4 of these overlapping loci include genes that are known drug 
targets. Though the overlap between these two groups of associations is well known, 
the population level effect of the variants causing Mendelian lipid syndromes has not 
been systematically evaluated. 
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Figure 6. All lipid trait associated loci grouped into Mendelian dyslipidemia causing, 
genome-wide association (GWA) and drug target loci. Modified and updated from Kathiresan 
and Srivastava 2012. 
2.6 Genotype imputation 
Genotype imputation means statistical inference of missing genotypes in the genetic 
marker data based on a common haplotype reference set. Genotype imputation is most 
commonly used to achieve the same marker set in different cohorts by imputation 
with same reference dataset, and to widen the SNP marker set at the same time. 
(Marchini and Howie 2010). However, as imputation results in uncertain genotype 
information, the uncertainty in the imputation should be taken into account in the 
analysis stage.  
Genotypes obtained from the genotyping chips are pairs of alleles for which the 
haplotype structure needs to be estimated before the actual imputation. Most of the 
imputation programs do the haplotype phasing at the same time with the imputation 
using either pre-defined recombination rates (Howie et al. 2009, Marchini et al. 2007, 
Scheet and Stephens 2006) or by estimating the recombination probabilities from the 
reference dataset (Li et al. 2010). Based on the recombination map, together with the 
possibility of spontaneous mutation, the haplotypes for a genotyped individual can be 
structured as a mosaic of the reference haplotypes. This stage of the imputation can be 
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performed using Hidden Markov Model (HMM) where either the reference 
haplotypes or clusters of reference haplotypes are hidden stages and the transition 
probabilities are based on the recombination and expected mutation rates.  
As the mosaic structure of each haplotype of the genotype data has uncertainty, 
different statistical methods are needed to define the certainty of imputation result in 
an iterative manner. For this, there are multiple different methods including Markov 
Chain Monte Carlo simulation, forward-backward algorithm and expectation-
maximization algorithm (Marchini and Howie 2010). The result of the imputation is 
either three probabilities, one for each allele combination at that locus, or a number 
between 0-2 representing the dosage of one of the alleles observed, which is equal to 
the expected value of observing a specific genotype based on the probabilities of the 
three genotypes. The uncertainty of the imputation at a specific locus should be taken 
into account in the association analysis. This can be done by treating genotypes as 
dosages (value between 0-2, as was described above) in linear or logistic regression 
models instead of certain allele counts (values 0, 1, or 2) and is implemented in most 
of the genome-wide analysis programs (Marchini et al. 2007). 
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3 AIMS OF THE STUDY 
In this study, genetic loci with associations for circulating blood lipids are searched 
using genotyped and imputed datasets of European ancestry. The overall aim is to 
discover novel genetic markers and biological pathways behind the general 
population lipid variation. More specifically this study aims to identify and 
characterize 
1) common variants (project I) 
2) gene-environment interactions (project II) and 
3) low-frequency and rare variants (project IV) 
associated to HDL-C, LDL-C, TC, and TG. 
In addition, in order to better understand the effect of different imputation reference 
sets to the association analyses, the performance of a general European reference and 
a population specific reference is evaluated in a founder population (project III). 
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4 MATERIALS AND METHODS 
4.1 Study samples 
4.1.1 Genome-wide data cohorts 
Most of the cohorts used in association screening are from European Network of 
Genomic and Genetic Epidemiology (ENGAGE; www.euengage.org) partner 
research centers. ENGAGE was a five-year research project funded by the European 
Commission under the 7th Framework Programme-Health Theme. Over 20 research 
organizations have taken part in this network with over 80,000 samples with GWA 
data and a vast variety of phenotype measures available.  
A summary of the cohorts used in the genome-wide association screens is presented 
in Table 1. Of the listed 43 cohorts, most (25 cohorts) are population based cohorts 
not selected based on any specific criteria. Exceptions are the twin cohorts (ATR, 
DK-TWIN, FTC, NTR, STR, Twingene, and TwinUK), birth cohorts (58BC-DIL, 
58BC-WTCCC, HBCS, and NFBC1966), and case-control cohorts (DGI, type 2 
diabetes; GenMets, metabolic syndrome; GERMIFSI & II, MIGen, myocardial 
infarction; NTRNESDA; depression or anxiety; PredictCVD, cardiovascular 
diseases). All study subjects in each of the participating cohorts have signed a written 
consent for the usage of their blood samples and phenotypic measurements. More 
information can be found from the original publications. 
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4.1.2 Adipose tissue expression dataset 
The adipose tissue expression data, used in project II, consists of 54 individuals with 
both genome-wide SNP data through genotyping with Illumina HumanHap 370K and 
mRNA based gene expression data available. These 54 individuals have been 
originally selected as unrelated individuals belonging to the highest and lowest 10% 
of the HDL-C distribution in the EUFAM study with dyslipidemic Finnish families 
(Pajukanta et al. 1997). 
4.1.3 Datasets with lipoprotein sub-particles 
In project II we used additional lipoprotein phenotypes that were available from the 
Young Finns Study (YFS) and Northern Finland Birth Cohort 1966 (NFBC1966) 
cohorts. These more specific lipoprotein fractions in native serum samples were 
measured using proton nuclear magnetic resonance (NMR) spectroscopy. The 
measured lipoprotein subclasses used in this study were chylomicrons and largest 
VLDL particles (particle diameters from approximately 75 nm upwards), five 
different VLDL subclasses: very large VLDL (average particle diameter 64.0nm), 
large VLDL (53.6 nm), medium-size VLDL (44.5 nm), small VLDL (36.8 nm), and 
very small VLDL (31.3 nm); intermediate-density lipoprotein (IDL) (28.6 nm); three 
LDL subclasses: large LDL (25.5 nm), medium-size LDL (23.0 nm), and small LDL 
(18.7 nm); and four HDL subclasses: very large HDL (14.3 nm), large HDL (12.1 
nm), medium size HDL (10.9 nm), and small HDL (8.7 nm). 
4.1.4 Health2000 imputation quality and CNP tagging test set 
In project III we tested the imputation quality by imputing a test set of 2212 
individuals selected from the National Health 2000 survey as metabolic syndrome 
cases and matched controls (Kristiansson et al. 2012). The dataset has been genotyped 
using Illumina HumanHap 610K genotyping chip, which has 598,203 SNPs and 
620,901 CNP probes before quality control assessment.  
Material and methods 
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4.2 Imputation reference haplotypes 
4.2.1 HapMap project phase 2 and 3 references 
HapMap project phase 2 dataset (HM2) includes 60 founder individuals from 30 
family trios from Utah with European ancestry (CEU) (International HapMap 
Consortium 2007). The HM2 imputation reference set has been used in project I 
follow-up analyses, in project II in imputation of all the GWA cohorts and in project 
III as one of the imputation references compared. The number of SNP variants in the 
HM2 reference is ~2.5 million. 
HapMap project phase 3 dataset (HM3) is an extended version of the HM2 dataset 
(International HapMap 3 Consortium 2010). In addition to the HM2 samples it 
includes new populations and thus has a higher number of haplotypes. In project III, 
we used HM3 CEU and Toscany in Italy (TSI) samples (total N = 200) and a smaller 
randomly selected reference panel from the HM3 CEU, HM3-s, with 81 samples that 
equals the size of the Finnish HM3 reference set described below. The number of 
SNP variants in the HM3 reference is ~1.5 million. 
4.2.2 Finnish HapMap3 samples  
The Finnish population-specific imputation reference set (FIN) consists of 81 
individuals of which 41 were collected from the late-settlement area (LSFIN) and 40 
from the capital area representing the general Finnish population. Samples were 
genotyped using Illumina Human 1M-Duo and Affymetrix Genome-Wide Human 
SNP Array 6.0 chips and quality controlled with the exact same methods as the HM3 
reference set. After QC, the dataset had a total of 1,163,280 SNPs. In addition, in 
project III, we combined the HM3 and FIN reference set to form a HM3+FIN 
reference set with a higher number of reference haplotypes. Similarly, we combined 
LSFIN and HM3 to form a combined reference dataset, HM3+LSFIN. Only SNPs 
overlapping between the reference panels were used in the combined reference. The 
difference in the HM3 CEU and TSI as well as LSFIN and FIN reference datasets are 
represented in Figure 7, which shows the population structure with the first two MDS 
components derived from the genome-wide SNP data. 
 45 
 
Figure 7. Genome-based differences between European and Finnish individuals. The y- and 
x-axis represent multidimensional scaling components 1 and 2, respectively, derived using 
genome-wide marker data. CEU: Individuals from Utah with European ancestry, TSI: 
Individuals from Toscany in Italy, FIN: Finnish individuals from capital area, LSFIN: Finnish 
individuals from late-settlement area. 
4.2.3 1000 Genomes project reference 
1000 Genomes (1000G) project is an international project aiming to map human 
genetic variation, both SNPs and structural variation like CNPs, down to allele 
frequency of 1% (1000 Genomes Project Consortium 2010). In this project, samples 
from multiple different populations worldwide have been collected and sequenced. 
The imputation reference set used in project IV (Phase I interim release, June 2011) 
includes a total of 1094 samples described in Table 2. The number of SNP variants in 
the 1000G reference panel is ~37 million. 
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Table 2. 1000 Genomes project reference haplotype origins and numbers. 
Population Abbreviation Number of samples in the reference 
African-Americans in Southwest US ASW 61 
Utah residents with Northern and Western 
European ancestry CEU 87 
Han Chinese in Beijing, China CHB 97 
Han Chinese South CHS 100 
Colombian in Medellin, Colombia CLM 60 
Finnish in Finland FIN 93 
British in England and Scotland GBR 89 
Iberian populations in Spain IBS 14 
Japanese in Tokyo, Japan JPT 89 
Luhya in Webuye, Kenya LWK 97 
Mexican ancestry in Los Angeles, California MXL 66 
Puerto Rican in Puerto Rico PUR 55 
Toscani in Italia TSI 98 
Yoruba in Ibadan, Nigeria YRI 88 
This table presents the number of samples of each population in the 1000 Genomes project 
Phase I interim release reference dataset. 
4.3 SNP and CNP genotyping 
Genotyping of each of the study cohorts has been done using different genotyping 
microarrays and are presented in Table 1. In general, when using oligonucleotide 
microarray genotyping, the array includes probes for DNA sequences, which are 
developed to bind into a specific genetic locus with polymorphism. In case of the 
Illumina microarrays, both alleles at a specific locus have their own probes. As each 
of the probes have unique fluorescence coloring, the intensity of the colors defines the 
individual’s genotype at that locus. If an Affymetrix array is used, each SNP/CNP has 
only one probe with only one fluorescence color but the probe binds differently for 
the different alleles. Therefore, the individual’s genotype can be computationally 
defined from the overall intensity of the one color.  
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Once the intensities have been recorded for each of the SNPs/CNPs, they are 
clustered computationally using, for example, three-component mixture model to 
differentiate genotypes from each other (Teo et al. 2007). As an example, in Figure 8 
below, intensity clusters are presented for one SNP where each dot represents one 
individual. The red cluster represents individuals homozygous for the one allele and 
blue for the other. The green cluster represents heterozygous individuals. Intensity 
values that do not fit into the clusters are set to missing. 
 
Figure 8. Genotype intensity clustering of one SNP. This figure is an example of the intensity 
clustering into three genotypes colored with red, green, and blue. Each dot in the figure 
represents intensity for one SNP and one individual. Grey dots at the bottom of the picture are 
intensities that do not fit into the clusters and are set to missing. 
4.4 Statistical methods 
4.4.1 Lipid phenotype measures, quality control and transformations 
Circulating blood lipids, HDL-C, LDL-C, TC, and TG, have been measured using 
basic enzymatic methods. In some cohorts no measured LDL-C was available in 
which cases the LDL-C has been estimated using Friedewald formula (Friedewald et 
al. 1972). Before the association analysis individuals taking lipid-lowering medication 
have been removed from the sample set together with individuals showing highly 
deviating lipid values. For case-control cohorts the data was stratified by the disease 
status in all GWA screens.  
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Table 3. Summary of the phenotype adjustments and transformations in GWA 
screens 
Screen Stratified by sex 
Raw TG values 
logarithmized Covariates 
Residual transformations 
and standardizations 
Common variant 
screen Yes Yes age Standardized 
Interaction screen 
(sex-interaction) No Yes age, age
2 inverse normal 
transformation 
Interaction screen 
(other interactions) Yes Yes age, age
2, sex inverse normal transformation 
Low-frequency and 
rare variant screen Yes No 
age, age2, C1, 
C2, C3 
inverse normal 
transformation 
Table shows the differences in the phenotype value treatment between the three association 
screens. raw TG: directly measured triglyceride laboratory values, age2: squared age, C1-3: 
multidimensional scaling components 1-3. 
In association screens, the raw lipid values, Y, were adjusted for covariates listed in 
Table 3 using linear regression model ! = ! + !!"#!×!!"#1+⋯+!!!"#!×!!"#ℎ + !!, (1) 
where ! is the model intercept, !!"#!… !!!"#! are the effect estimates for covariates 
1…h and ! is a vector with resulting residuals. For twin datasets the mean of the 
monozygotic twin-pair was used as a phenotype value Y. The resulting residuals from 
the adjusting model, !, were standardized to ensure same distribution for SNP effect 
estimates in each of the meta-analyzed cohort. The standardized residuals were then 
used as phenotype in the association analyses and are thus later referred to as !!"#.  
In interaction screen, two sets of residuals were derived. First set, which was used in 
all but sex-interaction analyses, was adjusted for age, age2, and sex using linear 
regression model (1). Age2 was added to the models after the first project to 
additionally account for the nonlinear effect of age on lipid levels. TG values were 
log-transformed before adjustments. The other set, which was used only in sex-
interaction analyses, was adjusted for age and age2 only. The resulting residuals of 
both sets were inverse normal transformed before the association analyses to ensure 
the similar effect estimate distributions across the cohorts. In inverse normal 
transformation, the adjusted phenotype values are set to N(0,1) distribution by their 
rank. The raw quantitative epidemiological phenotypes used in the interaction testing, 
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body mass index (BMI) and waist-to-hip ratio (WHR), were inverse normal 
transformed as well. 
In low-frequency and rare variant screen, the raw lipid values were stratified by sex 
and adjusted for age, age2 and, in some cohorts with known population stratification 
issues, for first three MDS components to avoid spurious associations. The resulting 
residuals were inverse normal transformed before the association analyses. 
4.4.2 Genotype data quality control 
Before association analysis of genotyped SNPs or imputation, the genotype data of 
each GWA cohort were cleaned using several quality control (QC) checks. These 
include thresholds for minor allele frequency (MAF) or minor allele count (MAC), 
Hardy-Weinberg equilibrium Fisher’s exact test P-value, SNP call rate, excess 
heterozygosity, excess relatedness and population stratification using MDS. In 
addition, in projects II and IV, post-imputation QC thresholds for MAF, MAC, and 
imputation quality were used. 
As each of the projects has different cohorts contributing and varying thresholds 
between cohorts, the specific criteria are not presented here but can be found from the 
original publications. 
4.4.3 Genotype imputation 
After the genotype data QC described above, in project I follow-up stage and projects 
II, III, and IV the genotype data was imputed to cover a denser SNP set. Genotype 
imputation uses the LD structure and allele frequencies observed in the genotype and 
reference data haplotypes to statistically infer missing genotypes or untyped SNPs. 
The imputation starts by assigning the genotype data as a mosaic of the reference 
haplotypes. This can be achieved using HMM where the hidden states are reference 
haplotypes and transition probabilities are calculated based on the LD structure in the 
reference dataset. 
Let us assume we have !!  individuals in the genotyped data and !! haplotypes in the 
reference dataset. Number of haplotypes is always twice the number of individuals. 
Let us denote the genotype vector of individual i over the M markers with !! ∈0, 1, 2 ! , ! = 1…!! . The goal is to define phased haplotypes for the genotype 
data, !! = !!,!…!!,!!  using reference dataset haplotypes, !! = !!,!…!!,!! . 
Material and methods 
50 
In addition, as HMM is iterative, let us denote the current best guess haplotypes for all 
the other individuals than i as !!,!!. HMM model can now be formulated as ! !!,! !! ,!! ,!!,!! ,!= ! !!,! !! ,!! ,!! ,!!,!! ,! ! !! !! ,!! ,!!,!! ,!!! !, (2) 
where !! = !! ,!! !!! !! .!!,!!  is a hidden state formed by a pair of sampled 
haplotypes from the reference dataset that are consistent with the observed genotype, !! . The two probabilities in the model (2) are emission probability and prior 
probability, respectively.  
If the imputation is done using predefined recombination rates (like in IMPUTE, 
Marchini et al. 2007), the prior probability, ! !! !! ,!! ,!!,!! ,! , is estimated using 
Markov chain simulation where the state transition probabilities between markers m 
and ! + 1 are ! !!,! → !!,!!! !! ,!! ,!!,!! ,!
=
!!!!! + 1− !!!!!! ! ,!!!!!!!!!!!!!!!!!!!!!!!!!!,! = !!,!!!,!!,! = !!,!!!
!!!!! + 1− !!!!!! 1− !!!!!! ! , !!,! = !!,!!!,!!,! ≠ !!,!!!!!,! ≠ !!,!!!,!!,! = !!,!!!1− !!!!!! !,!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!,! ≠ !!,!!!,!!,! ≠ !!,!!!
 
 
where ! = 2 !! − 1 + !! , !! = 4!! !×!100!×!!!, !! ! is the effective population 
size and !! is the recombination rate between markers m and ! + 1. 
In case the recombination rate is estimated from the dataset (like in MACH, Li et al. 
2010) the transition probabilities are defined using crossover parameter !! which is 
the proportion of crossovers between markers m and ! + 1. 
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! !!,! → !!,!!! !! ,!! ,!!,!! ,!!
=
!!! ! ,!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!,! = !!,!!!,!!,! = !!,!!!!!! 1− !! + !!! ! , !!!!!,! = !!,!!!,!!,! ≠ !!,!!!!!!!!,! ≠ !!,!!!,!!,! = !!,!!!1− !! + !!! ! !,!!!!!!!!,! ≠ !!,!!!,!!,! ≠ !!,!!!
 
In both cases the initial state of the Markov chain is  
! !!,! !! ,!! ,!!,!! ,! = ! !!,! !! ,!! ,!!,!! ,! = 1!!!. 
Now the prior probability can be reformulated with joint probability ! !! !! ,!! ,!!,!! ,!= ! !!,! !! ,!! ,!!,!! ,! ! !!,! → !!,!!! !! ,!! ,!!,!! ,!!!!!!! . 
The emission probability ! !!,! !! ,!! ,!! ,!!,!! ,!  in the model (2) can be 
reformulated with a joint probability as well. As this probability is modeling the 
spontaneous mutation possibility, meaning that the reference haplotype may have a 
different allele than the genotype data because of a spontaneous mutation but still be 
part of the same haplotype. The emission probability can thus be defined as 
! !!,! !! ,!! ,!! ,!!,!! ,! = ! !!,! + !!,! → !!,!!!!! !, 
where !!,! + !!,! → !!,!  is based on the probability of spontaneous mutation, !, 
defined with 
! = 12+ 2! 1!!!!!!!  
and the probabilities listed in Table 4. 
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Table 4. Formulae for the probabilities of spontaneous mutation. 
 
!!,! 
0 1 2 
!!,! + !!,! 
0 1− ! ! 2!(1− !) !! 
1 !(1− !) !! + 1− ! ! !(1− !) 
2 !! 2!(1− !) 1− ! ! 
In this table the probabilities of spontaneous mutation from one genotype to another are 
presented. 
Using the estimated the mosaic structure of the !!, the imputation is done by copying 
the unobserved SNP alleles based on the mosaic structure. This procedure is repeated 
multiple times and the probability of each possible genotype at a locus can be 
calculated over the iterations.  
The dosage genotype used in the association analysis can be derived from the 
probabilities resulting from the imputation as the expected value for the genotype, for 
example for a marker m and individual i ! !!,! = 0!×!! !!,! = 0 + 1!×!! !!,! = 1 + 2!×!! !!,! = 2 . 
We have used MACH imputation in the project III to especially account for the 
population differences as MACH does not require pre-defined recombination rates, 
which are only available for general European populations. MACH has additionally 
been used in the imputations in projects I and II. The imputations in project IV were 
performed using IMPUTE v2.0. 
4.4.4 Association and meta-analysis methods 
In association analyses of all three screens, linear regression models were used. 
Summary of the association analysis methods used in the screens are presented in 
Table 5 and more detailed statistical models are presented in the following chapters. 
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Table 5. Summary of the association analysis methods 
Screen Association analysis Meta-analysis Other 
Common variant screen Simple linear regression model 
Inverse variance 
weighted  
Interaction screen Interaction model Inverse variance weighted 
eQTL association with 
simple linear regression 
model 
Low-frequency and rare 
variant screen 
Simple linear 
regression model 
Inverse variance 
weighted 
Conditional association 
using linear regression 
model with SNP-
adjusted phenotype 
Association analysis methods used in the three screens together with follow-up association 
methods.  
4.4.4.1 Simple linear regression model 
In direct association screens (projects I and IV), a simple linear regression model  !!"# = !! + !!×!!! + !!!, (3) 
was applied for each SNP genotype, !!, ! = 1…!, where M is the total number of 
SNPs in the dataset. !!"#!is a vector with transformed residuals resulting from the 
adjustment model (1) described earlier, !! is the model intercept (more specifically 
estimated mean phenotype value for individuals with 0 genotype in m:th SNP), !! is 
the effect estimate for the m:th SNP and !! is vector with the residuals assumed to be 
normally distributed.  
In the common variant screen, only directly genotyped SNPs were used with allele 
dosage values of 0, 1, and 2 as opposed to the continuous SNP dosages used in the 
low-frequency and rare variant screen as the datasets had been imputed. The 
expression quantitative trait locus (eQTL) association analysis for the interacting SNP 
was done using similar linear regression model (3) where the !!"# has been replaced 
by the gene expression intensity. 
4.4.4.2 Conditional association analysis 
Conditional association analyses were performed using SNPTEST (Marchini et al. 
2007, Marchini and Howie 2010), which in addition to adjustments listed in Table 5, 
adjusts !!"# on the conditioning SNP  !!"# = ! + !!"#$×!!!"#$ + !!"#$ 
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and in the simple linear regression association model  (3)  !!"# was replaced with !!"#$.  
4.4.4.3 Interaction model 
In the interaction screen, the gene-environment interaction model was defined as  !!"# = !! + !!×!!! + !!×!! + !!×!!!×!! + !!!, 
where !! is the effect estimate of the environmental factor, E, and !! is the effect 
estimate of the interaction term, !!×!, on the adjusted phenotype. The interaction 
term represents deviation from the additive SNP effect.  
4.4.4.4 Inverse variance weighted meta-analysis 
The cohort specific effect estimates for the association, !!! (I and IV) and for the 
interaction, !!!  (II) were meta-analyzed using inverse variance weighted meta-
analysis for each !"#! over the participating cohorts, k, by calculating the combined 
effect estimate 
!!"#$! = (!!!×! !!!)!!!!  
and combined standard error estimate  
!!"#$! = 1!!!! !, 
where  
!!! = 1!!!!! 
and !!! is the standard error for the effect estimate in cohort k for SNP m. This meta-
analysis method is directly implemented in R package MetABEL (extension for R 
library GenABEL, Aulchenko et al. 2007) as well as in METAL (Willer et al. 2010) 
and GWAMA (Mägi and Morris 2010) software tools 
4.4.5 CNP tagging 
In project III we tested if CNP tagging would improve using founder population 
specific reference set in tag-SNP selection. First we selected the SNP with the highest 
correlation with each of the CNPs in three different reference sets (FIN, HM3, and 
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combined HM3+FIN) independently. We then calculated the correlation coefficients 
for each of the CNP – tag-SNP pairs in the H2000 test set. These CNP – SNP 
correlations were used to compare the performance of the reference sets. 
4.4.6 Allele score, risk prediction and population variance explained 
In project I, a weighted allele score for lipid associated SNPs was derived to test for 
the combined association of the SNPs on cardiovascular diseases. In addition, the 
allele scores were used to test how much the SNPs explained of the total lipid trait 
variability. 
The allele score was calculated using effect estimate weighted sums in Rotterdam 
Study cohort, monozygotic (MZ) twin cohorts, and NFBC1966 cohort. The effect 
estimates were calculated using all but the estimation cohort (dropped out one at a 
time) to control for possible bias. For each trait, the SNPs with genome-wide 
significance (P-value < 5×10-8) were selected together with the previously associated 
SNPs and a trait specific allele score for each individual i was calculated using 
formula 
!"#$%! = !!"#$!,!×!!!! !!,!!, 
where M is the number of associated SNPs for the trait and !!,! is the genotype for 
individual i at a marker m. Markers used in the allele score calculation of each trait 
are listed in Table 6. 
To test whether the allele scores are associated to clinically defined 
hypercholesterolemia (serum total cholesterol over 6.5 mmol/l) or Intima media 
thickness (IMT) in Rotterdam Study, where clinical end-points and longitudinal data 
was available, we used a logistic regression model !1− ! = !!!"#$%!!!"#$%×!"#$% 
where ! is prevalence of the clinical end-point, !!"#$% is the model intercept and !!"#$% is effect estimate for the allele score, !"#$%. 
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Table 6. Markers used in the allele score calculation of each trait 
Trait rsID CHR Locus Publication (if not selected based on the project I) 
HDL-C 
rs2144300 1 GALNT2 Kathiresan et al. 2008 
rs6754295 2 APOB  
rs2083637 8 LPL  
rs3905000 9 ABCA1  
rs7395662 11 MADD  
rs12272004 11 APOcluster Willer et al. 2008 
rs2338104 12 MMAB-MVK Willer et al. 2008 
rs1532085 15 LIPC  
rs1532624 16 CETP  
rs2271293 16 LCAT  
rs4939883 18 LIPG  
LDL-C 
rs11206510 1 PCSK9 Kathiresan et al. 2008 
rs646776 1 CELSR2  
rs693 2 APOB  
rs6756629 2 ABCG5  
rs3846662 5 HMGCR  
rs12670798 7 DNAH11  
rs174570 11 FADS1-2-3  
rs2228671 19 LDLR  
rs16996148 19 NCAN-CILP2 Kathiresan et al. 2008 
rs157580 19 APOE  
TC 
rs10903129 1 TMEM57  
rs10889353 1 DOCK7  
rs646776 1 CELSR2  
rs693 2 APOB  
rs6755629 2 ABCG5  
rs3846662 5 HMGCR  
rs6987702 8 TRIB1  
rs174570 11 FADS1-2-3  
rs2228671 19 LDLR  
rs2304130 19 NCAN-CILP2  
rs2075650 19 APOE  
TG 
rs1167998 1 DOCK7  
rs673548 2 APOB  
rs780094 2 GCKR  
rs2240466 7 MLXIPL  
rs10096633 8 LPL  
rs17321515 8 TRIB1 Kathiresan et al. 2008 
rs12272004 11 APOcluster  
rs4775041 15 LIPC Kathiresan et al. 2008 
rs16996148 19 NCAN-CILP2 Kathiresan et al. 2008 
rs439401 19 APOE  
In this table, all single nucleotide polymorphisms (SNPs) used in the allele score calculation 
have been listed by trait. SNPs include markers with significant association in the common 
variant screen as well as previously published SNP markers. The source of the marker in case 
not found in our screen can be found from the last column. CHR: chromosome, HDL-C: high-
density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, TC: total 
cholesterol, TG: triglycerides. 
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In addition, to test the risk for incident coronary heart disease (CHD), we used cox 
proportional hazards model (Cox 1972) ℎ ! = ℎ!(!)!!!"#$%×!"#$% 
where ℎ !  is hazard at time t, ℎ!(!) is baseline hazard at time t and !!"#$%×!"#$% 
are similar as above in the logistic regression model. 
To assess the proportion of lipid trait variance explained in three different datasets 
(Rotterdam Study, MZ-twins, and NFBC1966) by the allele scores in project I, sex-
stratified age-adjusted phenotypes, Yadj, were used. We compared the proportions of 
variance explained by allele score and BMI using analysis of variance on linear 
models !!"# = !!"#$% + !!"#$% !×!!!"#$ + !!"#$% ! !!"# = !!"# + !!"# !×!!"# + !!"# ! 
where !!"#$% is effect estimate for the allele score and !!"# for BMI. 
The variance attributable for each of the variables in the model was calculated by 
comparing the sum of squares of the explanatory variable, SSScore or SSBMI, to the total 
sum of squares, SStotal of the model. The sums of squares are calculated as !!!"#$% = !!"#! − !!"#$%! − !!"# !! !!, !!!"# = !!"#! − !!"#! − !!"# !! !!, !!!"!#$!"#$% = !!!!"#$% + !!"#$%!!! !!and !!!"!#$!"# = !!!"# + !!"#!!! !, 
where !!"# is the arithmetic mean of the !!"# values. Using the SS-values above, the 
proportions of variance are calculated 
!!!"#$% = !!!"#$%!!!"!#$!"#$% !!!and!!!!!!"# = !!!"#!!!"!#$!"# !!. 
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In project IV, the population variance explained was calculated using multiple linear 
model for sex, age, age2, and population stratification (fist three components from the 
MDS) adjusted phenotype 
!!"# = !!"#$ + !!×!!!!!!! + !!"!"!!, 
where M is the number of SNPs to be tested. The proportion of variance was then 
calculated as above. 
4.4.7 Rare variant analysis 
In project IV, in addition to single SNP association analyses, a gene-based association 
analysis for rare variants (MAF < 1%) was performed. The analyses were run using 
GRANVIL (Mägi et al. 2012) that models the cumulative amount of rare variants per 
individual in a gene against the phenotype. More specifically, a linear regression 
model !!"# = ! + !!"#"! + !!, 
where !! is a vector of ratios !!"!#!!"#" (the number of rare SNPs in which the individuals 
carry rare alleles / total number of rare SNPs in the gene), was applied for each gene 
in each of the tested 15 cohorts (listed in Table 1). Genes were here defined as coding 
sequence only and transcript start and end points were defined based on the UCSC 
genome browser developed by the University of Santa Cruz. The cohort specific 
summary statistics were combined using sample size weighted meta-analysis. For the 
gene-based rare variant analyses, significance threshold of P-value < 1.7 × 10-6 
corresponding to a Bonferroni correction for 30,000 genes (0.05 / 30,000) was used. 
4.5 Pathway analysis for eQTL results 
In project II, the expression quantitative locus (eQTL) association analysis was done 
for one genome-wide significant SNP, rs6448771 using genome-wide gene 
expression intensities in 54 adipose tissue samples to identify genes whose expression 
is altered by the polymorphism. Genes showing at least suggestive eQTL association 
(P-value < 0.01) were selected for the follow-up pathway analyses. Lower P-value 
threshold was also used to capture the associations where the power was not sufficient 
to show significant association.  
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In the pathway analysis, the selected 633 genes were ranked by their P-value and the 
enrichment of the genes on particular biological pathways was assessed using 
Ingenuity Pathway Analysis (http://www.ingenuity.com). The significance for the 
pathways was corrected for multiple tests using Benjamini-Hochberg correction 
(Benjamini and Hochberg 1995). 
4.6 Association power simulation 
To demonstrate the impact of imputation quality and CNP tagging differences with 
different reference datasets in project III on power to detect association we performed 
a simulation experiment. First a SNP/CNP variant was randomly sampled from the 
empirical test dataset and recorded the observed correlations between the real 
genotype and imputed variant observed in the quality testing (or correlations between 
the CNP and the tag-SNP in the CNP power simulation) with different reference sets 
(R2) together with the SNP/CNP allele frequency (MAF). This information was used 
to create dosage genotypes, !!!"# ,  for 10,000 individuals based on binomial 
distribution B(2, MAF). Using the resulting genotype vector the phenotype vector, !!"# ,!was created using predefined effect size, ! !!"# = !!×!!!"# + !!"#!, 
where !!"#was randomly sampled from N(0,1) distribution. The simulations were  
performed for effect sizes ! ∈ 0.05, 0.06,… ! , 0.29, 0.30 . Then the values in the 
genotype vector !!"# were randomly changed based on the B(2, MAF) distribution 
until the correlation between the original vector and the changed vector was the R2 
sampled in the first step. Using this new genotype vector !"#_!!"# corresponding to 
a imputed SNP variant or CNP tag-SNP a linear regression model  !!"# = !!×!!"#_!!"# + ! 
was created to test for the association. For each of the effect sizes !  40,000 
simulations were performed and the resulting P-values recorded. The power to detect 
genome-wide significant association was calculated by dividing the occurrences of 
significant associations by the number of simulations (40,000). 
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4.7 siRNA silencing experiments 
In project IV, the two most promising candidate genes, TM6SF2 and CD300LG were 
followed-up using small interfering RNA (siRNA) silencing in Huh7 cell line, which 
is a hepatocellular carcinoma cell line and is mostly used in studies with liver 
expressed genes. Targeted siRNA breaks down the mRNA right after the transcription 
and thus silences the gene expression. The expression levels of CD300LG in Huh7 
cell line before silencing were mean = 113.4 (standard deviation, s.d = 3.23) and of 
TM6SF2 mean = 248.2 (s.d = 53.0). The siRNA silencing effect (3-4 biological 
replicates for 3-4 replicates of test siRNA/experiment and 9 replicates of control 
siRNAs) was determined using fluorescence dying and imaging. The fluorescence 
intensities were normalized using ratio to negative control. More specific methods can 
be found from the original publication. 
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5 RESULTS 
5.1 Summary of the genome-wide screen results  
In our three GWA screens for circulating blood lipids we were able identify a total of 
95 significantly (P-value < 5×10-8) associated loci. One of these loci was an 
interaction locus and 94 loci showed direct association with at least one of the lipid 
traits. For all of the loci, the association showed consistent effect across the 
contributing study cohorts. In the first two screens the associated SNPs were 
positioned in or close to genes, which are enriched in highly relevant biological 
pathways (Table 7). In addition, we show function in lipid metabolism for two new 
genes, CD300LG, encoding protein with a previously known function as cell surface 
glycoprotein (Clark et al. 2009) but with no previously proven role in lipid 
metabolism specifically, and TM6SF2, whose function was shown by Kozlitina et al. 
2014 in a knock-out mouse model during the review stage of our publication. The 
results of each individual screen are presented in more detail in Chapters 5.2, 5.3 and 
5.5. 
Table 7. Summary of the genome-wide association screen results 
Screening method 
(maximum N) 
Chapter 
SNP data Number of loci with P-value < 5×10-8 Functional evidence 
Common variant 
screen 
(N = 22,562) 
 
Chapter 5.2 
Directly 
genotyped SNPs  22 
Associated SNPs enriched on following biological 
pathways: 
Cholesterol metabolic process (HDL-C, LDL-C, TC) 
Sterol metabolic process (HDL-C, LDL-C, TC) 
Lipid transporter activity (TC) 
Response to nutrient (TC) 
Regulation of protein transport (TC) 
Lipid transport (HDL-C) 
Monocarboxylic acid metabolic process (HDL-C) 
Alcohol metabolic process (HDL-C) 
Steroid biosynthetic process (LDL-C) 
Gene-environment 
interaction screen 
(N = 43,903) 
 
Chapter 5.3 
HM2 imputation 1 
Interactive SNP associated to expression of genes 
enriched on following biological pathways: 
Lipid metabolism  (TC: WHR interaction) 
Carbohydrate metabolism (TC: WHR interaction) 
Low-frequency and 
rare variant screen                 
(N = 62,166) 
 
Chapter 5.5 
1000Genomes 
imputation 
93 
(21 loci overlapping 
with common 
variant screen) 
3 candidate missense variants belonging to genes 
(CD300LG, TM6SF2) affecting lipid metabolism in liver 
cells 
This table summarizes the results of the three genome-wide association screens: common 
variant screen, interaction screen, and low-frequency and rare variant screen. N: number of 
samples, SNP: single nucleotide polymorphism, HM2: HapMap phase 2 imputation reference, 
HDL-C: high density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, 
TC: total cholesterol, WHR: waist-to-hip ratio. 
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5.2 Genome-wide screen of common variant associations  
In our genome-wide meta-analysis of 16 population cohorts of European descent 
(maximum N = 22,562) we were able to identify 22 loci with genome-wide significant 
association (P-value < 5×10-8) with one or more lipid traits (HDL-C, LDL-C, TC, and 
TG) with consistent effect across the cohorts. Of these loci, 16 were previously 
known to be associated to lipids and 6 loci were novel (LDLRAP1, ABCG5, DNAH11, 
MADD, FADS2/3, and LCAT) (Table 8). Out of the 22 loci, nine showed significant 
association with more than one lipid trait. 
Table 8. Genome-wide significant associations in the common variant screen 
Locus SNP CHR Position Build37 
Alleles 
(effect/ 
other) 
EAF 
Primary 
associated 
trait 
Secondary 
associated 
trait(s) 
β  
(SE) 
P-value 
(N) 
LDLRAP1 rs10903129 1 25768937 G/A 0.54 TC  0.061 (0.010) 
5.4×10-10 
(22550) 
ABCG5 rs6756629 2 44065090 G/A 0.92 
TC  0.145 (0.022) 
1.5×10-11 
(17472) 
 LDL-C 0.157 (0.025) 
2.6×10-10 
(12706) 
DNAH11 rs12670798 7 21607352 G/A 0.24 LDL-C  0.089 (0.015) 
6.1×10-9 
(12695) 
MADD rs7395662 11 48518893 G/A 0.61 HDL-C  -0.073 (0.011) 
6.0×10-11 
(17917) 
FADS1-2-3 rs174570 11 61597212 G/A 0.83 
LDL-C  0.110 (0.015) 
4.4×10-13 
(16153) 
 TC 0.088 (0.014) 
1.5×10-10 
(20916) 
LCAT rs2271293 16 67902070 G/A 0.87 HDL-C  -0.129 (0.016) 
8.3×10-16 
(17910) 
New loci with genome-wide significant association in the common variant screen have been 
listed in this table. SNP: single nucleotide polymorphism, CHR: chromosome, EAF: effect 
allele frequency, SE: standard error of effect estimate β, N: number of samples, TC: total 
cholesterol, TG: triglycerides, LDL-C: low-density lipoprotein cholesterol, HDL-C: high-
density lipoprotein cholesterol. 
5.2.1 Gender differences in associated common variant loci 
In addition to the GWA screening, we tested the significant loci for possible 
differences in effects between males and females. Two out of 11 TC associated loci 
(HMGCR: βmales = 0.049, βfemales = 0.117, P-value = 0.0013 and NCAN: βmales = 0.234, 
βfemales = 0.110, P-value = 0.0019) showed sex-interaction with P-value < 0.0045 
corresponding to a Bonferroni correction for 11 independent tests. Similarly, one of 
the eight loci showing association for HDL-C (LPL: βmales = 0.149, βfemales = 0.006, P-
value = 0.006) showed difference with P-value < 0.0062 corresponding to a 
Bonferroni correction for eight independent tests. 
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5.2.2 Disease risk assessment for the associated common SNPs 
As one of the screening datasets, Rotterdam Study, had both longitudinal and clinical 
data available, we tested the disease risk prediction of identified lipid-associated 
SNPs for possible cardiovascular disease end-points. We tested five different allele 
risk scores created using SNPs associated to (1) HDL-C, (2) LDL-C, (3) TC, (4) TG, 
or (5) any of the following (combined allele risk score) for association with intima 
media thickness (IMT), hypercholesterolemia, and incidence of coronary heart disease 
(CHD). We found that TC allele risk score was significantly associated to 
hypercholesterolemia (P-value < 0.001), IMT (P-value = 0.001), and CHD (P-value = 
0.042). When including the measured TC values to the association models, 
hypercholesterolemia and IMT associations remained significant but the association 
for CHD did not. In addition, the most significant clinical end-point association (for 
hypercholesterolemia) showed significant improvement in disease prediction model 
over the well-known clinical risk factors, age, sex, and BMI (area under the receiver-
operating-characteristic curve increase from 0.63, confidence interval (CI) = [0.61–
0.64] to 0.66, CI = [0.65–0.67]). 
5.2.3 Enrichment on biological pathways 
To further evaluate our SNP associations on a biological level, we selected all genes 
with significant SNP association (P-value < 5×10-8) to identify Gene Ontology 
pathways into which the associated genes are enriched. As a result, the most 
significant enrichment for TC associated genes was found to ‘cholesterol metabolic 
process’, for HDL-C associated genes to ‘lipid transport’, for LDL-C genes to ‘sterol 
metabolic process’ and for TG genes to ‘lipid catabolic process’. 
5.2.4 Population variation explained by the allele scores 
Finally, using three independent datasets, we estimated the proportion of population 
variation in lipids that could be explained using the allele scores. The estimated 
proportions of variance explained by the allele scores were 4.8%, 3.4%, 3.9%, and 
3.0% for HDL-C, LDL-C, TC, and TG, respectively. Nevertheless, this is quite a 
small fraction of the total lipid variation suggesting that using this analysis approach 
we had only just scratched the surface of the genetic background of lipid metabolism. 
Results 
64 
5.3 Gene-environment interactions on lipids 
Motivated by the suggestive sex-interaction results in the GWA-screening of lipid 
associated loci, we initiated a GWA-screen of gene-environment interactions on 
lipids. Using 18 population-based European cohorts (maximum N = 32,225) we tested 
interaction effects of BMI, WHR, sex, smoking, alcohol usage on HDL-C, LDL-C, 
TC, and TG. When combining the results of these 18 cohorts at 2.5 million genetic 
markers by HapMap 2 imputation we were able to identify 18 suggestive interaction 
loci (P-value < 1×10-6). Lower P-value threshold was used to follow-up associations 
where power was not sufficient to show significant association. 
As a follow-up, SNPs with suggestive interaction association were tested in additional 
8 cohorts (maximum N = 14,889). In the meta-analysis of all 26 cohorts one SNP, 
rs6448771, showed genome-wide significant interaction association (P-value < 5×10-
8). To ensure that the finding was not a false positive, we even further tested the 
association in two additional cohorts (N = 7,813), which showed similar interaction 
effect and lead to a combined P-value = 4.79×10-9 in the meta-analysis of all 28 
cohorts (N = 43,903). At this locus, the genotype of rs6448771 modifies the effect of 
WHR on TC in a way that G allele homozygous individuals had 0.19 sd-units [0.13 - 
0.25] higher TC per one sd-unit change in WHR when A allele homozygous 
individuals only had 0.12 sd [0.09 – 0.16] (Figure 9). Quite surprisingly, the SNP had 
no direct effect on WHR or TC (P-values 0.51 and 0.46, respectively).  
 
Figure 9. Demonstration of the interaction effect of rs6448771. In the figure the x-axis is the 
waist-to-hip ratio (WHR) where pear means thin waist and wide hip, and apple vice versa. Y-
axis is the total cholesterol level. The lines represent the effect between cholesterol and WHR 
for different genotype classes.  
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5.3.1 Interaction characterization with lipoprotein sub-particles 
As enzymatically measured lipoprotein concentrations only measure the total amount 
of free cholesterol in particular lipoprotein particles and not the size that reflects the 
“age” of the particle (nascent, mature, remnant) we further tested the interaction effect 
of rs6448771 with WHR on NMR measured lipoprotein sub-particle concentrations in 
NFBC1966 and YFS cohorts. We found that the interaction had nominal significance 
on the concentration of large HDL particles (β = 0.538, P-value = 0.0186), large 
VLDL particles (β = -0.466, P-value = 0.0291) and total serum TG (β = -0.454, P-
value = 0.0343). 
5.3.2 Adipose tissue eQTL association analysis 
To identify possible causal genes in the associated area, we examined eQTL 
associations of the SNP rs6448771 in 54 individuals with genome-wide SNP data and 
adipose tissue expression data available. We found two nearby genes with nominal 
cis-eQTL associations, protocadherin 7, PCDH7 (eQTL P-value = 0.027) and 
cholecystokinin A receptor, CCKAR (P-value = 0.017). To get a broader view of the 
possible biological effect of the SNP, we selected all genes with cis-eQTL or trans-
eQTL P-value < 0.01 (total of 633 genes) to test the enrichment of the genes on 
biological pathways. This analysis was performed using Ingenuity Pathway Analysis 
software. We found enrichment of eQTL associated genes on ‘degradation of 
phosphatidylcholine’ and ‘degradation of phosphatidic acid’ biological functions both 
belonging to broader categories ‘Lipid Metabolism’ and ‘Carbohydrate Metabolism’. 
5.4 Genotype imputation and CNP tagging quality in 
founder population samples 
As Finnish datasets, with unique population characteristics, have contributed greatly 
to both GWA-screens and in the interaction screen in which we were using HM2 
imputed SNP data, we decided to test whether founder population imputation and 
CNP tagging accuracy would improve using a population specific reference set. To 
test this we took 2,212 samples from the Health 2000 survey with genotype SNP and 
CNP data available through genotyping with Illumina HumanHap 670K genotyping 
chip.  
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5.4.1 Imputation quality comparison 
By masking and re-imputing SNPs that were not present in the last generation 
Illumina HumanHap 370K genotyping chip on chromosome 21 using five different 
reference haplotype sets (HM2, HM3, FIN, HM3-s, and HM3+FIN) we found that the 
imputation quality, measured by correlation between the true and imputed genotype 
(R2), was improved for both common (from median R2 = 0.956 to R2 = 0.964) and 
low-frequency variants (from median R2 = 0.898 to R2 = 0.912) when using the 
population specific reference instead of HM3 reference sets with European samples 
(Table 9). The improvement was even more profound when combining the general 
European and Finnish reference sets (median R2 = 0.977 and 0.941 for common and 
low-frequency SNPs, respectively). When comparing the imputation quality 
improvement with FIN and HM3-s with the same number of haplotypes, the FIN 
reference set performed better. The improvement in the imputation quality was 
greatest for the SNPs with low allele frequency and in areas with low LD in the test 
dataset. Usage of the subpopulation reference set from the late-settlement area 
combined with HM3 (LSFIN+HM3), when imputing samples with the same late-
settlement ancestry, did show improvement over the HM3 reference set but not over 
the HM3+FIN dataset.  
Table 9. Quality measures from imputation of the Health 2000 dataset. 
Reference dataset Number of haplotypes 
Median R2 
common SNPs 
Median R2 low-
frequency SNPs 
HM2 120 0.943 0.853 
HM3-s 162 0.947 0.837 
HM3 352 0.956 0.898 
FIN 162 0.964 0.912 
FIN+HM3 514 0.977 0.941 
Quality measures from the imputation with HapMap 2 (HM2), smaller HapMap 3 reference 
of 81 individuals selected randomly from the HapMap 3 CEU samples (HM3-s), HapMap 3 
(HM3), population specific extension (FIN) and the HapMap 3 extended (FIN+HM3) 
references.  R2 is the square of the linear correlation between imputed allele dosage and 
genotyped SNP. Common SNPs are defined as having MAF ≥ 0.05 and low-frequency as 
MAF < 0.05.  
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5.4.2 CNP tagging comparison 
Using the same test dataset and three of the imputation reference datasets with 
available CNP information (HM3, FIN, HM3+FIN) we additionally tested if the 
choice of reference set would improve CNP-tagging quality. For each of the CNPs we 
selected three SNPs, each with different reference set, and compared the SNP - CNP 
correlations between HM3 and FIN as well as between HM3 and HM3+FIN. In 
general, the correlations were quite similar (median R2 = 0.412, 0.424, and 0.448 for 
HM3, FIN, and HM3+FIN, respectively). However, we found that there was a subset 
of CNPs where the tagging was greatly improved when changing the reference dataset 
but also a subset where the tagging was worse in both comparisons. Based on the 
correlations, the HM3+FIN reference set showed most robust results by improving the 
correlation from HM3 reference by at least 0.05 in 5.3% of the CNPs whereas only 
1.8% of the CNPs showed 0.05 lower correlation values. Using FIN dataset instead of 
HM3 the corresponding percentages were 9.6% and 8.5%.  
5.4.3 Effect of the quality gain on association studies 
To address the effect of these quality changes in both imputation quality and CNP 
tagging a simulation experiment was performed at association analysis level. The 
simulation demonstrated that the power to detect association was most improved 
among SNPs with MAF between 0-3% and CNPs with allele frequency of 5-10% 
(Figure 10). However, high or modest effect sizes (0.25-0.3 in sd units) are needed to 
have sufficient power at such SNPs and CNPs even with genotyped variants. 
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Figure 10. Simulation of the effect of imputation quality and copy number polymorphism 
(CNP) tagging improvement to power to detect association. In panel a), results for single 
nucleotide polymorphisms (SNPs) and CNPs with minor allele frequency (MAF) 10-50% are 
presented. Similarly, panel b) MAF 5-10%, c) 3-5%, d) 0-3%. In the legend, “Ideal tag-SNP” 
means tagging correlation of 1. HM3: HapMap project phase 3 reference set, HM3+FIN: 
combined reference set of HM3 and population specific reference. 
5.5 Impact of low-frequency variants in lipid variation 
5.5.1 Genome-wide screen for associations 
To screen for low-frequency variants associated to blood lipids (HDL-C, LDL-C, TC 
and TG), we used 22 cohorts with European ancestry (total N = 62,166) with 
imputation based on the 1000 Genomes project reference set. Using data of 9.6 
million directly genotyped or successfully imputed common, low-frequency and rare 
SNPs, we found 93 genome-wide significant (P-value < 5×10-8) loci of which 83 were 
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previously known and 10 were new (Table 10). Out of the newly identified loci, four 
showed low-frequency variant as a lead-SNP. 
Table 10. Loci showing genome-wide significant association in 1000 Genomes 
imputed association screen 
Locus rsID CHR Position Build37 
Alleles 
(effect/ 
other) 
EAF 
Primary 
associated 
trait 
Secondary 
associated 
trait 
β  
(SE) 
P-value  
(N) 
PROX1 rs340839 1 214161820 A/G 0.47 TG  0.039 (0.06) 
4.4×10-10 
(54836) 
CEP68 rs2540948 2 65284623 T/C 0.65 TG  0.036 (0.006) 
6.6×10-9 
(59939) 
PRKAG3 rs78058190 2 219699999 G/A 0.95 HDL-C  0.141 (0.020) 
5.7×10-12 
(52934) 
ADAMTS3 rs117087731 4 73696709 T/A 0.01 TC  0.308 (0.051) 
2.3×10-9 
(23641) 
MTHFD2L rs182616603 4 75084732 T/C 0.01 
TC  0.374 (0.044) 
1.8×10-17 
(42905) 
 LDL-C 0.314 (0.045) 
2.1×10-12 
(38420) 
GPR85 rs2255811 7 112722196 G/A 0.25 TG  0.041 (0.007 
2.3×10-8 
(59962) 
RMI2 rs7188861 16 11454650 A/C 0.20 HDL-C  0.044 (0.008) 
6.9×10-9 
(60578) 
TM4SF5 rs193042029 17 4667984 T/G 0.99 TG  0.170 (0.029) 
8.1×10-9 
(50105) 
GATA6 rs79588679 18 19907770 C/T 0.83 LDL-C  0.049 (0.009 
3.6×10-8 
(53108) 
ZNF274 
rs117492019 
19 
58681861 G/T 0.81 LDL-C  0.047 (0.008) 
1.2×10-8 
(55371) 
rs12983728 58671267 G/A 0.84  TC 0.046 (0.008) 
4.9×10-8 
(58904) 
In this table loci with P-value < 5×10-8 in the low-frequency and rare variant screen with 1000 
Genomes imputed marker data have been presented. CHR: chromosome, EAF: effect allele 
frequency, SE: standard error of effect estimate β, N: number of samples, TG: triglycerides, 
HDL-C: high-density lipoprotein cholesterol, TC: total cholesterol, LDL-C: low-density 
lipoprotein cholesterol. 
Out of the previously known 83 loci, 11 were led by low-frequency SNPs in our data 
instead of common SNPs observed in the previous publications (Global Lipids 
Genetics Consortium et al. 2013, Teslovich et al. 2010). When testing for the 
independence of the identified low-frequency and previously observed common lead-
SNP in previously known loci using conditional association analysis, we found that in 
two loci (PCSK9 and MAFB) the previously known lead-SNP association was 
explained by the newly identified variant.  
In addition, when looking at the effect estimates and MAFs of the new and previously 
known GWA lead-SNP in an independent dataset of 5,119 individuals, we found that 
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in general the new GWA variants have lower allele frequency and higher estimated 
effect.  
5.5.2 Effect of known functional variants in associated loci 
In our screen, we were also able to see well-known lipid variants listed in the Online 
Mendelian Inheritance of Man (OMIM) database as a lead-SNP in four loci (PCSK9, 
GCKR, ANGPTL4, and APOE). To better understand the joint mechanism of known 
functional lipid SNPs and associations observed in our dataset, we searched OMIM 
database to gather all the SNP variants with known functional impact on lipid levels 
and confirmed the functionality of each of variant through a careful literature search. 
We found such variants in eight loci (PCSK9, CELSR2, GCKR, HLA-region, LPL, 
LIPC, CETP, and APOE) with genome-wide significant association in our GWA 
screen. The functional lipid SNPs explained the lead-SNP association (with original 
P-value < 5×10-8 and conditional P-value > 0.01 for the lead-SNP) in four of the 8 
loci. In the CELSR2 locus, the association was explained by rs12740374 (Musunuru 
et al. 2010b), in GCKR locus by rs1260326 (Beer et al. 2009) and in APOE by two 
variants, which were independent of each other but together explained the association. 
These two variants were rs7412 and rs429358, which define the APOE isoforms ε2, 
ε3, and ε4 (Weisgraber et al. 1981). In LIPC locus the association was explained by 
rs1800588 (Deep and Peng 2000) and rs113298164 (Durstenfeld et al. 1994) for TC 
and TG but not for HDL-C. 
5.5.3 Search for new functional candidate variants 
Motivated by the conditional analyses, we decided to search for new functional 
candidate variants by selecting missense mutations with similar predicted impact on 
protein level at loci in which there were no established functional lipid variants, and 
by conditioning the associations using these candidate variants. Formal conditional 
analysis was performed in four loci (MLXILP, MADD, SOST and NCAN-CILP2) with 
candidate damaging missense variants. In two of those loci (SOST, associated to TG 
and NCAN-CILP2, associated to LDL-C, TC, and TG) the functional candidate 
variants positioned in CD300LG and TM6SF2 genes explained the associations. One 
of the two candidate missense variants in the TM6SF2 gene was shown to associate 
with TC, myocardial infarction and nonalcoholic fatty liver disease (Holmen et al. 
2014, Kozlitina et al. 2014), and the TM6SF2 gene was shown to regulate liver cell 
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TG secretion (Mahdessian et al. 2014), during the review stage of the original 
publication. However, our study shows that both of the identified missense mutations 
in the locus are needed to explain the observed association. 
To ensure the effect of the two genes on lipid metabolism we additionally performed 
an siRNA knockdown experiment in the Huh7 liver carcinoma cell line. For 
CD300LG knockdown cell lines we observed a decrease on cellular neutral lipids (TG 
and cholesteryl esters) with all validated siRNAs. For TM6SF2 knockdown we 
observed a clear increase in neutral lipids, in line with our association results and a 
recent publication by Mahdessian et al. 2014. In addition, TM6SF2 knockdown cells 
were studied for LDL-uptake for which we observed inconsistent results, in 
accordance to the results by Blattmann et al. 2013.  
5.5.4 Population trait variance explained by low-frequency variants 
To better understand the overall effect of the low-frequency variants on population 
level lipid variation we used independent dataset of 5,119 individuals to estimate the 
proportion of variance explained by the common lead-SNPs compared to low-
frequency lead-SNPs. All lead-SNPs from the previously published studies (Global 
Lipids Genetics Consortium et al. 2013, Teslovich et al. 2010) and our low-frequency 
screen together with the well-established functional variants and new functional 
candidates were divided into two groups based on their allele frequency in the 
independent estimation dataset. The total trait variance explained by the common 
variants was 11.9%, 16.3%, 16.2%, and 8.2% for HDL-C, LDL-C, TC, and TG, 
respectively, whereas adding low-frequency variants into the model, we were able to 
explain 12.8%, 19.5%, 18.8%, and 9.3% of the variance. 
5.5.5 Association of gene-based rare variant accumulation on lipids 
In addition to low-frequency variants, we tested for rare variant associations using a 
gene-based test in 15 cohorts (maximum N = 30,463). By this approach we found that 
enrichment of rare non-synonymous variants in LIPC was significantly associated 
with HDL-C (P-value = 2.1×10-7). The gene-based association was independent of the 
lead-SNP association found in the GWA-screen. Similarly, in the APOcluster locus, 
accumulation of any type of rare variants in two genes (APOA5: P-value = 5.0×10-8 
and ZNF259: P-value = 1.5×10-11) showed association to TG and was only partly 
explained by the single SNP association (Table 11). 
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Table 11. Unconditional and conditional results for genes with significant 
enrichment of rare variants. 
Associated gene mean MAF Gene-based test        P-value 
GWA lead-SNP adjusted 
P-value 
LIPC* 0.26% 2.1×10-7 3.6×10-6 
ZNF259 0.25% 1.5×10-11 3.3×10-4 
APOA5 0.24% 5.0×10-8 4.3×10-5 
*Only non-synonymous variants were enriched.  
In this table, results for the gene-based tests and lead-SNP conditional analyses are presented 
for genes with significant enrichment of rare variants. MAF: minor allele frequency, GWA: 
genome-wide association.  
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6 DISCUSSION 
Statistically significant association between 95 genetic loci and circulating blood 
lipids were identified in this thesis work, with consistent effect across multiple 
European cohorts. The observed associations fall close to or into genes enriched in 
biological pathways involved in regulation and activity of lipid and carbohydrate 
metabolism. One of the identified 95 loci is the first published gene-environment 
interaction locus with genome-wide significant evidence for association. In addition, 
all the genetic information available at the end of this thesis project explained up to 
19.5% of the lipid trait population variation (for LDL-C), which corresponds to 
approximately 38% of the estimated LDL-C heritability of 0.51 (van Dongen et al. 
2013). 
6.1 Genome-wide screen for common SNP associations 
In project I, a total of 22 common SNP loci showed genome-wide significant 
association. Of these 22 loci, six had not been shown to associate with lipids in earlier 
studies but were replicated in project IV except for one locus. The association at a 
LDLRAP1 locus, that was not replicated in project IV, has been verified elsewhere 
(Teslovich et al. 2010). In addition to significant associations, we were also able to 
identify three loci in which the effects in males and females differed significantly 
suggesting sex-SNP interaction. The strongest sex-difference in effects was observed 
in the HMGCR locus for TC. HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A 
reductase) is a target for statin treatment, which lowers the circulating LDL-C (Endo 
1992). 
In further evaluation of the lipid associated SNPs, clinical endpoint data was tested 
against the allele scores. Results showed that the TC allele score was significantly 
associated to hypercholesterolemia, intima media thickness, and cardiovascular 
disease. These data suggest that genetic risk scores, especially the score formed with 
TC associated variants, could be useful in the early detection of future cardiovascular 
and dyslipidemic patients. 
Genetic information associated to each of the traits was also gathered and allele scores 
were created to evaluate the overall impact of the variants on population trait 
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variance. Though the estimates were close to ones for a well-established risk factor, 
BMI, the overall trait variance explained was still small suggesting that by looking at 
the common variant associations, only the peak of the genetic background of lipid 
levels could be seen.  
6.2 Gene-environment interaction screen 
In the genome-wide screen for gene-environment interactions (project II) the first 
genome-wide significant interactive SNP was identified. This SNP modified the effect 
of WHR on TC in a way that carriers of two G allele had on average 64% stronger 
relation between WHR and TC than individuals carrying two A alleles. The eQTL 
analysis of the modifying SNP pointed towards two possible candidate genes, PCDH7 
and CCKAR. CCKAR knockout rats have shown obesity, hyperglycemia, and type 2 
diabetes (Moran et al. 1998) suggesting this gene as a plausible candidate for the 
locus. 
Though successfully identifying an interaction, the most important result of the 
project was the lack of significant findings even though we had a total number of 
43,000 individuals in the analysis. This can be due to the model selection or variation 
in both phenotypes and environmental factors. More accurate biological measures of 
both lipoprotein particles and obesity could lead to a different result.  
6.3 Imputation and CNP tagging quality improvement 
The imputation quality and CNP tagging exercise (project III) showed that the usage 
of a population specific reference set brings clear added value to both imputation and 
tagging and affects the power in association analyses. The gain in quality and 
accuracy was more profound in areas with lower LD and MAF, and in 
imputation/tagging using the combined reference of both Europeans and Finns. The 
improvement in the imputation quality was already seen using the Finnish reference 
set alone, suggesting that the more similar LD structure and allele frequencies in the 
reference data improves the imputation. The improvement in the imputation quality 
using the combined reference instead of the Finnish reference is most likely due to the 
increased number of haplotypes together with increased variability among haplotypes 
increasing the probability to find the “matching” haplotypes.  
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6.4 Effect of low-frequency variants on lipid levels 
Project IV specifically aimed to screen for low-frequency variants affecting lipid 
levels. This was possible with the new 1000 Genomes imputation reference enabling 
the imputation of SNPs with MAF down to 0.5%. Using the dense and well-imputed 
data from 22 cohorts we identified 10 new lipid-associated loci. The newly identified 
variants in the screen have not yet been replicated in an independent dataset, but the 
large number of cohorts in the meta-analysis shows the association consistence across 
different datasets. In addition, in the PRKAG3 locus, there are two possible candidate 
genes: CYP27A1 (cytochrome P450, family 27, subfamily A, polypeptide 1), which is 
known to play a role in lipid metabolism (Chiang 1998) and PRKAG3 (protein kinase, 
AMP-activated, gamma 3 non-catalytic subunit), which is a regulatory subunit of the 
AMP-activated protein kinase, which has previously been shown to regulate lipid 
homeostasis (Kahn et al. 2005). In another new locus, PROX1 has been previously 
associated with type 2 diabetes (Dupuis et al. 2010). 
In addition to a discovery of ten new loci, of which four were driven by low-
frequency variants, a new GWA lead-SNP was identified in 79 of the previously 
identified 83 loci with genome-wide significant association in the meta-analysis. Out 
of these 79 loci, 11 were driven by low-frequency variants, which on average had 
three times higher estimated effect on the trait than the previously established lead-
SNPs. This also shows in the population level lipid variation explained by the low-
frequency variants, where adding the low-frequency variants on top of the common 
variants adds up to 3.2% (for LDL-C) to the amount of trait variance explained.  
6.5 Effect of known functional lipid SNPs 
To better understand the joint mechanism of known functional lipid SNPs and 
associations observed in this dataset, formal conditional association analysis was used 
in eight significant loci with well-characterized variants affecting lipid metabolism. 
When conditioning the association at loci with both significant association and known 
functional lipid SNP, in half of the loci (CELSR2-SORT1, GCKR, APOE, and LIPC) 
the well-known variants, originally identified using patient data, also explained the 
association at population level. In addition, when estimating the amount of general 
population lipid level variation explained by the tested functional lipid SNPs, the 
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estimates were as high as 1.7 − 6.2% showing that genetic variants causing severe 
dyslipidemia also contribute to general population lipid variation.  
6.6 Functional candidates 
To identify novel functional candidate variants in loci with no previously established 
functional lipid SNPs, SNPs with at least suggestive association on the trait were 
annotated and by formal conditional testing, four loci with candidate missense 
variants were observed and in two loci (SOST and CILP2) the variants explained the 
association. The explaining variants reside in genes CD300LG and TM6SF2. The 
effect of these candidate genes on lipid metabolism was further verified by siRNA 
knockdown experiments in liver carcinoma cells and a clear impact on relevant lipid 
measures in the silenced cell lines was observed. In addition, in a recent publication 
(Kozlitina et al. 2014) published during the review stage of the original publication 
IV, it was shown that one of the two missense variants we found in TM6SF2 leads to 
an increased liver TG content and decreased VLDL secretion in mice. 
6.7 Strengths and limitations 
In project I, the GWA screen for lipid-associated variants was performed using non-
imputed data as imputation methodology had not yet been evolved to handle large 
genome-wide SNP data. As the datasets were genotyped using different genotyping 
platforms the power to detect association was considerably lower at SNPs that were 
not overlapping between the different genotyping chips. This problem was taken into 
account in the projects II and IV where all the cohorts were imputed using the same 
imputation reference enabling analysis of 2.5 and 9.6 million polymorphic variants 
(for projects II and IV, respectively). 
In the phenotype quality control, individuals based on fasting status were not 
excluded. This may lead to increased variability in lipid measures, especially in TG, 
and could be the reason why in the project IV the amount of TG variance explained 
by the identified variants was considerably lower than the proportions of other studied 
lipid traits. 
In both association screens SNPs were assumed to have additive effect. This leads to 
less power in loci with true dominant or recessive effect. In addition,  in the latter 
screen (project IV) the traits were inverse normal transformed, which may have led to 
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decreased power. However, this transformation ensures that the normality assumption 
in linear model is achieved and that the resulting effect estimates have similar 
distribution across the cohorts, which is needed for unbiased meta-analysis. 
The suggestive sex-interactions found in the project I were not replicated in the 
interaction screen (project II) suggesting that the gender differences observed were 
either false positive findings or that the interaction effect was not strong enough to be 
observed in the first stage analysis in the interaction screen and therefore was not 
followed up in further datasets. This remains to be verified in further studies. 
In the interaction screen, interaction was defined as a deviation from the additive 
model. The result of finding only one significant association may be due to this 
decision and does not rule out the possibility of finding significant interactions using a 
different interaction definition. In addition, the phenotypes and environmental factors 
considered were quite broad from the biological point of view and usage of more 
refined measurement of both lipid metabolism, for example NMR-measures, and 
environmental factors, for example cotinine for smoking, could bring more power. 
In the project studying imputation quality and CNP tagging, Finnish data was used to 
demonstrate the gain in usage of a population specific reference set. The observed 
results could be due to the Finnish population, but as the gain in the imputation was 
most profound in areas with LD and MAF differences, we are confident that the 
results can be generalized to other founder populations as well. 
In project IV, a quality control threshold of minor allele count > 3 was used in each of 
the cohorts together with the meta-analysis threshold for SNPs that at least half of the 
studies needed to contribute. This means that variants with low-allele frequency have 
been excluded from multiple smaller studies and further from the meta-analysis even 
though they have had good imputation quality and more than three observations in the 
larger studies. Usage of different quality control thresholds could have resulted in 
significant associations that were not observed in our study. 
In all of the projects in this thesis we have used highly developed methodology and 
the largest imputation reference available at the time, combined with a high number 
of samples enabled by European-wide co-operation. For this, new undiscovered loci 
were found in all of the original publications. 
  
Conclusions and future aspects 
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7 CONCLUSIONS AND FUTURE ASPECTS 
Cardiovascular diseases cause most deaths worldwide, but despite this well 
acknowledged issue, there have not been great breakthroughs in the prevention of 
these diseases since the discovery of the lipid lowering effect of statin treatment. A lot 
of work and co-operation between fields of science is still needed to understand the 
mechanisms affecting and regulating lipid metabolism. 
In this thesis project, almost a hundred genetic loci associated with circulating blood 
lipids were identified and the loci showed enrichment in highly relevant biological 
pathways. This thesis shows the power of co-operation in the genetic research field, 
together with the fast evolving methodology, to successfully identify variants 
associated to complex traits. This power is clearly demonstrated by the population 
variance explained, where the difference between the first and last project is 
remarkable, mostly due to a denser SNP map, better imputation, inclusion of low-
frequency variants and larger sample size. However, there is still a lot of heritability 
that is not explained by the variants found so far. 
Part of the “missing” heritability probably lies in the regions that have already been 
associated with lipids, but determination of the true causal variants, and number of 
them per loci, still requires a lot of association and functional studies. These causal 
variants might have been missed in the association screening studies using chip-based 
genotype data and therefore the interest in genetic studies is starting to move towards 
sequencing studies, where even the rare polymorphic sites can be identified and tested 
for association.  
Sequencing of tens of thousands of samples needed to find significantly associated 
rare variants is still fairly costly. This study has shown that large and dense 
imputation references can be used to find low-frequency variants associated to 
complex traits with lower costs, and maybe in the near future, by adding population 
specific sequence-based reference haplotypes, could be further extended to cover rare 
variant imputation. 
In addition, the true causal variant may be a structural variation, which has been 
included in the genotyping chips and imputation reference sets but have been 
extremely difficult to define and test with certainty. The well characterized sequences, 
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well-imputed genotype sets, and improvement in the CNP assessing and clustering 
methods can be the key to identify structural variation associated to complex traits. 
However, even if the methodology and data improvement may give us more insight of 
the underlying causal variant, more functional studies are needed to show the effect 
on the transcription and translation level. This study was successful to show two 
genes with functional impact on lipid metabolism, but there are still more than a 
hundred loci where the functional evidence has not yet been shown.  
Once the causal variants have been identified and the functionality shown, they could 
be used to create predictive SNP sets for early detection of individuals with higher 
risk for unfavorable lipid levels and dyslipidemic diseases. This way, individuals with 
high genetic risk could be instructed at the clinics to lower their behavioral and 
environmental risk factors to reduce the overall risk. In addition, further functional 
studies of lipid-associated loci can reveal new possible drug targets for lipid levels 
giving more possibilities for balancing lipid levels. Overall, the genetic knowledge 
helps us to understand the biology behind lipid levels and other complex traits and 
therefore brings us closer to the individual level risk assessment, health care, and 
disease treatment. 
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